Quarterlytics / Financial Services / Insurance - Brokers / Aroa Biosurgery

Aroa Biosurgery

arx · ASX Financial Services
Claim this profile
Ticker arx
Exchange ASX
Sector Financial Services
Industry Insurance - Brokers
Employees 51-200
← All annual reports
FY2024 Annual Report · Aroa Biosurgery
Sign in to download
Loading PDF…
ANNUAL
   REPORT
2024
Unlocking regenerative
healing for everybody

ON FY23
%
12
Total
Revenue
ON FY23
%
12
Product
Revenue
ON FY23
%
73
Myriad™
Product Revenue 
$23.3 M
ON FY23
%1
Gross
Margin
Completion of 
first clinical pilot 
study for Enivo™  
2024 
HIGHLIGHTS

Results in Brief	
04
Chair’s Review	
06
CEO’s Report	
08
Board of Directors	
12
Executive Leadership Team	
16
Sustainability Report	
19
Directors’ Report	
26
Remuneration Report	
31
Directors’ Responsibility Statement	
41
Independent Auditor’s Report	
43
Consolidated Financial Statements	
51
Notes to The Consolidated Financial Statements	
57
Additional Information	
82
Glossary and Other Information	
88
Corporate Directory	
91
	
+ KEY DATES 
23 July 2024
Annual General Meeting of Shareholders 
30 September 2024
Financial Half Year End 
26 November 2024*
Half Year Results Announcement 
31 March 2025
Financial Year End 
This Annual Report is dated 24 June 2024 and is signed 
on behalf of Aroa Biosurgery Limited by Jim McLean, 
Independent Chair of the Board and Brian Ward,
Managing Director and CEO.
*Indicative date
CONTENTS
Jim McLean
Independent Chair 
of the Board	
Brian Ward 
Managing Director 
and CEO 

Annual Report 2024
 
Myriad
Sales
FY20
FY21
FY22
FY23
FY24
0
10
20
30
40
Total AROA
Product Sales
FY20
FY21
FY22
FY23
FY24
0
10
20
30
40
50
60
70
$69.1
MILLION
Total
Revenue 
12%
ON FY23
85%
Product
Gross Margin
1%
ON FY23
12
YoY
Growth
%
73
YoY
Growth
%
$29.5
MILLION
Cash
Balance 
RESULTS
IN BRIEF

5
Endoform
TM
Sales
0
10
20
30
40
FY20
FY21
FY22
FY23
FY24
TELA Bio 
Sales
0
10
20
30
40
FY20
FY21
FY22
FY23
FY24
Sales Team
0
10
20
30
40
50
60
FY20
FY21
FY22
FY23
FY24
Endoform
Myriad
Myriad Active
Accounts
0
50
100
150
200
250
FY20
FY21
FY22
FY23
FY24
Research & Development
Spend
0
5
10
15
FY20
FY21
FY22
FY23
FY24
ENIVO
Other
Capitalised
23%
30%
21%
20%
17%
Clinical
Evidence
156
81
0
20
40
60
80
100
120
140
160
FY20
FY21
FY22
FY23
FY24
Conference Proceedings
Publications
31
YoY
Growth
%
23
YoY
Growth
%
-7
YoY
Growth
%
-2
YoY
Growth
%
% of Product Sales

Annual Report 2024
The Company’s FY24 performance 
reflects consistent growth across 
key metrics, with an increase in 
total revenue of 12%. On behalf of 
the Board, I want to thank Brian 
and our people for their efforts.
As expected, Myriad has 
contributed to strong growth, and 
momentum continues to build 
within our US sales team, with 
31% year on year growth in active 
Myriad accounts. 
AROA’s cash position remains 
strong. We will continue to invest 
in building out the Company’s US 
sales team, to drive further growth 
and capitalise on the market 
opportunities for our high-margin 
Myriad products. 
We understand the importance of 
implementing sustainable business 
practices and remain focused on 
this at leadership level. Throughout 
FY24, the Company has made 
steady progress in this area, which 
is covered in our Sustainability 
Report, included within this Annual 
Report. 
As previously announced, Darla 
Hutton joined the Board in March 
2024. She brings over 25 years of 
international leadership expertise in 
life sciences commercial strategy, 
operations, sales, marketing, 
and data analytics, and is also 
experienced in guiding diversity 
policy. Her skills and expertise 
will help guide the Company’s 
expansion in North America and 
beyond.
During FY24, the composition of 
our permanent Board committees 
was adjusted, including to 
reflect the addition of Darla. 
These changes as well as current 
membership of each Board 
committee, are included in this 
Annual Report.
CHAIR’S
REVIEW
As AROA grows and 
matures, the Board remains 
focused on ensuring that 
the Company is well placed 
to deliver long term growth 
that is both sustainable
and profitable.

7
Darla’s appointment does not increase the number of Directors, 
as long-standing Board Member Steve Engle retired from the 
Company’s Board in March 2024. Over the past nine years, 
Steve’s insight and knowledge have helped to shape the Company’s 
direction. On behalf of the Board, I would like to thank Steve for 
his significant contribution to AROA and wish him well in his 
future endeavours.
AROA has a diverse, talented team, strong corporate strategy, and 
the fundamentals in place to deliver long term value to shareholders. 
We highly value the confidence of our shareholders in AROA as the 
company continues to grow and reach new milestones.
Jim McLean 
Independent Chair 
of the Board of Directors 
“Myriad sales continue to drive 
consistent growth, with our US 
sales team delivering a strong 
31% year-on-year increase in 
active accounts, demonstrating 
continued momentum for the 
product portfolio.”

Annual Report 2024
Last year brought a mix of 
successes and challenges for 
AROA.
The Myriad portfolio of products 
performed well, with our US sales 
team delivering 73% year-on-year 
sales growth. This growth was 
driven by expansion within existing 
accounts and growth in new 
accounts.
TELA Bio’s OviTex/OviTex PRS 
sales continued to perform 
strongly, increasing 41% on the 
previous year. During the first half 
of FY24, TELA Bio implemented 
inventory management 
improvements to minimise 
obsolescence which significantly 
reduced stockholding from 
approximately 33% of revenue 
in FY23, to around 22% in FY24. 
This initially dampened TELA 
Bio’s demand for the products, 
contributing to a 7% decline in 
AROA’s full-year OviTex/OviTex 
PRS revenue compared
to the prior year. Demand 
recovered in the second half to 
deliver a 19% increase in AROA’s 
H2 FY24 OviTex/OviTex PRS 
revenue. With these adjustments 
now behind us, we are confident 
that FY25 will see a return to our 
previous growth trajectory. We also 
expect TELA Bio’s optimised stock 
portfolio to smooth demand and 
bring both parties’ sales into closer 
alignment going forward.
	
+ Commercial operations
As noted above, Myriad sales 
were the key growth driver and 
contributed to 34% of total 
product sales. This result was 
delivered by our expanded field 
sales team, which increased from 
~40 in 2023 to ~50 in 2024 whilst 
yielding improved productivity 
across all categories of tenure. 
Sales efficiency remains a critical 
focus, and we will be launching 
further initiatives to continue 
that upwards trend. This includes 
leveraging our sales success 
in lower limb procedures and 
continuing to extend usage in 
We are continuing to 
build clinical evidence 
demonstrating the efficacy 
of our products in specific 
procedures, including 
how they compare with 
standard of care and 
alternative products. These 
studies provide a basis 
for promotional activities, 
clinical engagement,
and inform our
commercial strategy.
We also expect to leverage 
that data to demonstrate the 
financial benefits of using 
Myriad within hospitals, 
which may include shorter 
hospital stays, reduced 
follow up surgeries, lower 
rates of complications and 
reduced product costs. 
CEO’S 
REPORT

9
trauma, capitalising on the growing 
body of clinical and financial 
evidence that underpins our AROA 
ECMTM portfolio. With over 95% 
of US hospitals able to access 
AROA products through our 
contracts with group purchasing 
organisations, we are well placed 
for sustained growth. 
	
+ Clinical foundations
During FY24, the Myriad 
Augmented Soft Tissue 
Regeneration Registry (MASTRR) 
study completed its target patient 
enrolments of 300. MASTRR is 
AROA’s largest prospective study 
to date, evaluating Myriad MatrixTM 
and Myriad Morcells™ in a range of 
lower limb salvage, colorectal and 
trauma procedures. Activating each 
site and collecting data has been 
a key focus for our clinical team 
over the last two years. The data is 
currently being evaluated, and we 
expect to report on Myriad’s use in 
limb salvage in 130 patients in the 
first half of FY25.
“Throughout the coming year, 
we will focus on delivering 
strong top line growth, while 
also managing expenses to 
ensure profitability in FY25.”

Annual Report 2024
Two further studies assessing 
Myriad in trauma procedures are 
expected to be published later 
in FY25. One of these studies 
will examine the use of Myriad 
with negative pressure (NPWT). 
Recruitment for the Symphony 
Randomised Control Trial is also 
well advanced with 90 out of a 
total of 120 patients recruited as at 
31 March 2024. Interim reporting 
based on the first 60 patients is 
expected during the last quarter 
of this calendar year, and final 
reporting in the second quarter of 
next calendar year. 
We are continuing to build clinical 
evidence demonstrating the 
efficacy of our products in specific 
procedures, including how they 
compare with standard of care and 
alternative products. These studies 
provide a basis for promotional 
activities, clinical engagement, and 
inform our commercial strategy. We 
also expect to leverage that data to 
demonstrate the financial benefits 
of using Myriad within hospitals, 
which may include shorter hospital 
stays, reduced follow up surgeries, 
lower rates of complications and 
reduced product costs.
Overall, we now have 81 peer 
reviewed clinical publications, 
supporting the use of our AROA 
ECM products. 
	
+ Enivo
We remain focused on activities 
that support commercialisation of 
our second technology platform, 
Enivo, which offers a unique 
opportunity to address a currently 
unmet market need and deliver a 
step change in healing outcomes.
The Enivo platform represents
significant commercial potential, 
with an estimated total addressable 
market of more than US$1 billion, 
and it is expected to be used 
synergistically with AROA ECM 
products.
In FY24, we completed a pilot 
clinical study assessing the efficacy 
of the Enivo platform, with 
encouraging results. In FY25, we 
will focus on undertaking further 
clinical research necessary to 
support regulatory clearance.
	
+ Manufacturing operations
We are continuing to invest in 
increasing both process efficiency 
and our tissue manufacturing 
capacity. In FY24 we implemented 
a number of process improvements 
and took delivery of an additional 
freeze dryer, which will at least 
double our freeze-drying capacity. 
We expect to conclude the 
current program of expansion and 
upgrades in the first half of FY25. 
	
+ FY25 outlook
Throughout the coming year, we 
will focus on delivering strong top 
line growth, while also managing 
expenses to ensure profitability 
in FY25. As announced in May, 
we expect to deliver FY25 total 
revenue of NZ$80-87 million and 
a normalised EBITDA profit of 
NZ$2-6 million.1
We expect our expanded product 
portfolio to drive continued 
product revenue and gross margin 
growth through sales of our higher 
margin Myriad™ and Symphony™ 
products. 
We are also committed to 
undertaking further clinical studies 
on the Enivo platform to advance 
commercialisation.
	
+ Concluding remarks 
Delivering shareholder value 
remains our top priority, and we 
are focused on demonstrating 
that AROA is becoming a high 
growth, cashflow positive 
business. We have calibrated our 
strategy accordingly, and our 
passionate and driven team is 
united in its commitment to that 
outcome. AROA’s shareholders 
are instrumental to our mission to 
unlock regenerative healing for 
everybody, and we thank you for 
your continued support. 
Brian Ward 
Founder, Managing Director
and CEO 


Annual Report 2024
BOARD OF 
DIRECTORS
James McLean 
James (Jim) is a resident of New 
Zealand. He has over 25 years’ 
experience serving as chair, 
director, or an executive of research 
and technology businesses for 
both commercial and New Zealand 
Government organisations. In 
addition to AROA, Jim is also Chair 
of Prevar Limited.
He was Chair of the New Zealand 
Institute of Plant & Food Research 
and Chair of its predecessor 
HortResearch, as well as several 
private businesses and start-up 
companies. He served on the 
board of the then Foundation for 
Research, Science, and Technology 
including five years as Deputy 
Chair. Jim was an executive and 
director of Genesis Research & 
Development Corporation Limited 
during its early stages through to 
public listing. 
Before specialising in science 
and technology businesses, Jim 
held management positions with 
an international manufacturing 
business and spent thirteen 
years as a partner at chartered 
accountants, EY. His time at EY was 
focused on business strategy and 
included two years’ secondment to 
EY’s Washington DC office. 
Jim has a BSc (Hons) in Chemistry 
from University of Otago and 
a Post Graduate Diploma in 
Accounting from Victoria  
University of Wellington.
BOARD RESPONSIBILITIES
Chairman and independent 
non-executive director 
and member of the Audit 
Committee.
TERM OF OFFICE
Apointed 10 August 2011. 
Last re-elected
10 August 2022. 
Brian Ward 
Brian is the founder of AROA and 
a resident of New Zealand. He has 
held senior corporate roles in life 
sciences and health care companies 
for more than 25 years. He has 
extensive management experience 
in life science companies spanning 
clinical, technical, sales, marketing, 
corporate development and 
strategy having worked for a 
number of multinationals including 
Baxter, Beecham and SmithKline 
Beecham throughout the world. He 
has managed investments into New 
Zealand technology companies 
for the Foundation for Research 
Science and Technology, served as 
the founding CEO of NZBio, and 
has sat on a number of government 
and industry expert panels. 
Brian has been responsible for 
leading AROA’s growth from 
start-up through to the present. 
As CEO and a substantial 
shareholder in the Company, he is 
considered by the Board to not be 
an independent director. 
Brian is a graduate of Massey 
University with a Bachelor’s degree 
in Veterinary Science, a Member 
of the Royal College of Veterinary 
Surgeons (UK), and holds a Masters 
degree in Business Administration 
graduating with distinction. 
BOARD RESPONSIBILITIES
Managing Director
and CEO.
TERM OF OFFICE
First appointed
21 September 2007.

13
John Diddams 
John is a resident of Australia and 
has over forty years’ experience 
as a CFO, CEO and director of 
both private and publicly listed 
companies. John is currently the 
non-executive Chairman of xReality 
Group Limited (ASX:XRG), and is 
a non-executive director of Surf 
Lakes Holdings Limited and DIT 
AgTech Limited. 
John has extensive knowledge 
and experience in the practical 
application of ASX Listing Rules, 
Australian corporations law, 
international accounting standards 
and corporate governance 
principles. He heads a CPA firm 
providing corporate advisory 
services to SME and mid-cap 
companies and has managed 
the listing process, secondary 
capital raisings and ASX listings 
in a number of diverse industry 
sectors, including oil and gas, food 
and retail, telecommunications, 
adventure tourism, biotechnology, 
and the dental and medical sectors. 
John holds a Bachelor of 
Commerce from University of 
NSW, is a Fellow of the Australian 
Society of CPAs and a Fellow of 
the Australian Institute of  
Company Directors. 
BOARD RESPONSIBILITIES
Independent non-executive 
director and Chair of 
the Audit Committee 
and Member of the 
Remuneration & Nomination 
Committee. 
TERM OF OFFICE
First appointed
21 November 2019.
Last re-elected
3 August 2023.
Darla Hutton
Darla is a resident of the US 
and has been a director of Aroa 
Biosurgery since March 2024. 
She has more than 25 years of 
medical technology experience, 
including global leadership 
expertise in commercial strategy, 
operations, sales, marketing, 
healthcare analytics, lean and 
enterprise consulting. 
Darla is currently Vice President, 
Asia Commercial Operations and 
Marketing at Intuitive, pioneers in 
the field of robotic-assisted surgery 
and maker of the da Vinci surgical 
and ION diagnostic robot systems. 
Throughout her tenure at Intuitive, 
Darla has held commercial roles 
of increasing responsibility 
including Regional Sales Director, 
Vice President of Corporate 
Accounts-US, and Vice President 
Marketing, Market Access & 
Custom Hospital Analytics. In these 
roles, she has contributed to the 
expansion of Intuitive’s commercial 
operations capabilities and range 
of global offerings. In addition, 
Darla has served as a member of 
Intuitive’s Inclusion and Diversity 
Executive Council. 
Prior to Intuitive, Darla held 
commercial positions at other 
successful medical technology, 
pharmaceutical, and biotech 
companies, including Boston 
Scientific and GlaxoSmithKline,  
and spent her early professional 
career in the cardiac-thoracic 
nursing field. 
Darla holds a Bachelor of Science 
and Master of Science from the 
University of Tampa. 
BOARD RESPONSIBILITIES	
Independent non-executive 
director and Member of the 
Risk Committee since 
1 April 2024 
TERM OF OFFICE	
	
First appointed
22 March 2024.

Annual Report 2024
Philip McCaw
Philip (Phil) McCaw is a resident 
of New Zealand and is the 
Founding Partner of Movac, one 
of New Zealand’s leading venture 
capital funds. He led the original 
investment round into AROA in 
2008, has worked closely with the 
Company and has served on the 
Board since then. He is currently 
the Executive Chair and CEO of 
Author-IT Software Corporation, 
a software company that delivers 
component authoring solutions, 
enabled by AI, for the largest 
global pharmaceutical companies. 
He was also the Chair of the 2023 
New Zealand Government’s Startup 
Advisors’ Council, established 
to help identify and address the 
opportunities and challenges facing 
high growth start-up businesses. 
Phil has over 20 years’ experience 
investing into New Zealand 
technology companies and helping 
to guide their growth. He was an 
early investor in Trade Me, New 
Zealand’s leading on-line trading 
community, which was sold to 
Fairfax in 2006. Phil was also an 
early investor into PowerByProxi, a 
wireless power technology spin-out 
from Auckland University, which 
was sold to Apple in 2018. 
Outside of Movac, Phil remains an 
active angel investor and maintains 
a personal angel investment 
portfolio. He is a strong advocate 
for the development of the 
entrepreneurial and early-stage 
investment eco-system in New 
Zealand and was the past Chair 
of the Angel Association of  
New Zealand. 
Prior to starting Movac, Phil spent 
10 years with Deloitte Consulting 
working in New Zealand and  
the US.
As a substantial shareholder in 
AROA, Phil is considered by the 
Board to not be an independent 
director. 
Phil has a Bachelor of Business 
Studies (Senior Scholar) from 
Massey University.
BOARD RESPONSIBILITIES
Non-executive director 
and member of the 
Remuneration & Nomination 
Committee 
TERM OF OFFICE
First appointed 5 March 
2008. Last re-elected
20 July 2021. 
Dr. Catherine Mohr 
Catherine is a New Zealand citizen 
and resident of the US. She has 
over 30 years’ experience across 
a diverse range of fields, including 
engineering, healthcare, alternative 
energy, aerospace and global 
entrepreneurship. 
Her expertise spans many areas 
related to AROA’s next stage 
of growth, including medtech 
product research and development, 
FDA approvals, product 
commercialisation and surgery 
technology innovation. 
She has been President of the 
Intuitive Foundation since 2018. 
Prior to leading the Foundation, 
Catherine held senior roles at 
Intuitive Surgical, including 
Vice President of Strategy and 
Director of Medical Research. 
Intuitive Surgical is a pioneer in the 
robotic-assisted surgery field and 
developed the da Vinci surgical 
robotic system which is used in 
millions of surgical procedures 
across the globe every year.
Catherine is also on the board of 
directors for FINCA International 
and cofounded VeriSure, where 
she invented the LapCap™, the first 
of a new category of laparoscopic 
surgery enabling products. 
Catherine holds a Bachelor of 
Science and Master of Science 
in Mechanical Engineering 
from Massachusetts Institute of 
Technology (MIT) and Doctor 
of Medicine from the Stanford 
University School of Medicine.
BOARD RESPONSIBILITIES
Independent non-executive 
director and member of the 
Risk Committee. Chair of the 
Remuneration & Nomination 
Committee since 1 April 2024
TERM OF OFFICE
First appointed 1 November 
2022. Last re-elected
3 August 2023.

15
John Pinion
John is a resident of the US. He has 
over 30 years of global experience 
leading biologic, small molecule 
pharmaceutical, gene therapy and 
device operations across Asia, 
Europe and the Americas. His 
expertise and leadership spans 
engineering, quality, manufacturing 
and translational sciences. He 
joined Ultragenyx in July 2015 
and currently holds the role 
of EVP, Translational Sciences 
and Chief Quality Operations 
Officer. He provides leadership 
for Ultragenyx’s translational 
sciences functions which includes 
Pharmacology and Toxicology, 
Research and Bioanalytical 
Development, as well as GxP 
Quality and Compliance and CMC 
Analytical QC. 
As a key member of Ultragenyx’s 
executive leadership team 
reporting directly to the CEO, 
he also contributes to ongoing 
business development, clinical 
development, commercial and 
strategic planning activities. 
John is also an advisory board 
member for Celestial Therapeutics, 
Inc., a biopharmaceutical company 
focused on the development 
and commercialisation of 
next-generation novel and ground-
breaking mRNA vaccines and 
therapeutics for the treatment and 
prevention of a variety of infectious 
diseases, rare diseases and cancers. 
John has previously held 
operational and senior leadership 
roles in Genentech (subsequently 
Roche post Genentech acquisition, 
as Senior Vice President and Global 
Head of Quality and Compliance 
for Pharma Technical Operations) 
and Baxter International’s Renal, 
Bioscience, Parenterals and Device 
divisions. 
He holds a B.S. in Mechanical 
Engineering from West Virginia 
University.
BOARD RESPONSIBILITIES	
Independent non-executive 
director, Chair of the Risk 
Committee and member of 
the Audit Committee 
TERM OF OFFICE	
	
First appointed 1 February 
2015. Last re-elected
20 July 2021. 
Steven Engle 
Steve is a resident of the US. 
He has over 20 years’ executive 
leadership experience with public 
biotech companies developing 
breakthrough products in 
metabolic, autoimmune, oncologic 
and infectious disease areas.
Steve is the CEO and executive 
director of Gradalis Inc., a late- 
stage biopharmaceutical company 
focused on the development 
and commercialisation of novel 
personalized therapeutics to 
treat cancer. He is also the 
non-executive Chairman of the 
board of Prescient Therapeutics 
Ltd. (ASX: PTX), an ASX listed 
clinical stage oncology company, 
and executive Chairman of 
Author-it Software Corporation, a 
developer of authoring information 
solutions for pharmaceutical and 
biotechnology companies. Steve 
also runs Averigon, an advisory 
firm to the life science industry 
on matters ranging from business 
development to management 
team coaching.
He was previously CEO of CohBar, 
a clinical stage biotechnology 
company developing mitochondria-
based therapeutics to treat 
age-related diseases and extend 
healthy lifespan. Prior to that, 
he held roles as Chairman and 
CEO of XOMA Corporation, 
a leader in the development 
of therapeutic antibodies and 
antibody technologies, and La Jolla 
Pharmaceutical Company, which 
discovered the biology of B cell 
tolerance, developed the first B cell 
toleragen for lupus patients, and 
received an approvable letter from 
the FDA. Earlier, he served as Vice 
President of Marketing for Cygnus, 
a drug delivery systems company, 
where he helped to gain FDA 
approval and launch Nicotrol for 
smoking cessation. 
He is a former director of industry 
associations, BIO, BayBio and 
BIOCOM, and was a member of the 
board of the Lupus Foundation of 
America. 
Steve holds M.S.E.E. and B.S.E.E. 
degrees from the University of 
Texas with a focus on biomedical 
engineering. 
BOARD RESPONSIBILITIES
Independent non-executive 
director, Chair of the 
Remuneration & Nomination 
Committee and member of 
the Risk Committee until
31 March 2024.
TERM OF OFFICE
First appointed 1 April 2015. 
Retired 31 March 2024. 

Annual Report 2024
Brian Ward 
James Agnew
Chief Executive Officer, 
Founder and Managing Director
Brian is the founder of AROA 
and a resident of New Zealand. 
He has held senior corporate 
roles in life sciences and health 
care companies for more than 
25 years. He has extensive 
management experience in life 
science companies spanning 
clinical, technical, sales, marketing, 
corporate development and 
strategy having worked for a 
number of multinationals including 
Baxter, Beecham and SmithKline 
Beecham throughout the world. He 
has managed investments into New 
Zealand technology companies 
for the Foundation for Research 
Chief Financial Officer and Joint 
Company Secretary
James joined AROA’s management 
team in 2013 and has over 20 years’ 
experience in business and finance. 
He has extensive experience in 
corporate finance, investment 
management, M&A, strategic and 
operational planning, contractual 
management and negotiation, 
international taxation and 
compliance, including US GAAP.
In 2011, James was a finalist in the 
Young Financial Manager of the 
year at the Annual CFO Awards. 
Prior to this role, he was the VP 
of Finance & Operations for MXM 
Science and Technology, served as 
the founding CEO of NZBio, and 
has sat on a number of government 
and industry expert panels. 
Brian has been responsible for 
leading AROA’s growth from 
start-up through to the present. 
Brian is a graduate of Massey 
University with a Bachelor’s degree 
in Veterinary Science, a Member 
of the Royal College of Veterinary 
Surgeons (UK), and holds a Masters 
degree in Business Administration 
graduating with distinction. 
Mobile (a division of the Meredith 
Corporation) based in New 
York, overseeing all international 
subsidiaries following the 
acquisition of The Hyperfactory 
Ltd (NZ high growth technology 
company) where he held the role 
of Group Financial Controller. In 
his earlier career, James worked 
in public practice providing 
accounting and business advisory 
services to a diverse range of 
successful New Zealand companies.
James holds a Bachelor of Laws 
and Bachelor of Commerce from 
the University of Auckland.
EXECUTIVE 
LEADERSHIP 
TEAM 

17
Dr. Barnaby May
Chief Scientific Officer
Barnaby joined AROA’s 
management team in 2008. He 
completed his doctoral thesis 
on the design and synthesis of 
novel HIV protease inhibitors 
at the University of Canterbury, 
New Zealand. He subsequently 
undertook postdoctoral studies 
in 2000 at the University of 
California San Francisco (UCSF). 
During this time, he established 
and led a drug discovery program 
targeting human prion diseases, 
and successfully identified a 
compound that underwent 
immediate clinical studies. Barnaby 
developed additional related 
research programs in the areas 
of protein misfolding diseases, 
parasitic diseases, computational 
and structural biology. In 2003, he 
accepted an invitation to a faculty 
role at UCSF where he built and 
led a drug discovery program. This 
program spanned target and lead 
identification, high-throughput 
screening, medicinal chemistry, 
and pre-clinical pharmacokinetics. 
In 2004, Barnaby joined InPro 
Biotechnology as Scientific 
Director to lead product 
development of prion-related 
medical devices and diagnostics. 
After 8 years abroad, he returned 
to New Zealand in 2008 and joined 
AROA.
Yasmin Winchester
Vice President Quality, Regulatory 
and Sustainability
Yasmin joined AROA in 2014 
and has held several roles in the 
quality space. Her role covers a 
wide scope, overseeing quality 
assurance, as well as regulatory 
affairs, health and safety, and 
sustainability. Yasmin’s role is 
responsible for developing and 
implementing AROA’s social 
and sustainability approach to 
achieve long-term stability and 
sustainability of our operations, 
while continuing to deliver medical 
devices that are safe and effective 
for use.
Before joining the AROA team, 
Yasmin held roles in Quality 
Assurance at Glaxo Smith Kline and 
Johnson & Johnson Medical.
Yasmin holds a Bachelor of Science 
with a major in Biology from the 
University of Waikato.
Rod Stanley
Chief Technology Officer
Rod joined AROA in 2013 and has 
over 15 years’ experience in medical 
device design and manufacturing.
Rod is responsible for managing 
the technical operations of the 
organisation and providing 
technical direction related to 
product development, project 
management, manufacturing,
and distribution. 
Prior to joining AROA, Rod worked 
in development of novel polymer 
coatings for microfluidic devices 
at Industrial Research Limited. 
Rod’s professional expertise 
includes chemical processing of 
biomaterials, and implementation 
of sterilisation processes. 
During his time at AROA, Rod’s 
focus has been on process design 
and transfer into manufacturing, 
redevelopment and scale-up 
activities for the Auckland site, 
as well as overseeing routine 
production activities. 
Rod holds a Bachelor of Science 
and a Master of Science from the 
University of Otago.


19
SUSTAINABILITY 
REPORT 
We are pleased to provide an update on our sustainability journey through 
this year’s Sustainability Report. 
At AROA, we continue to focus on contributing to a more sustainable 
future for everybody. Throughout FY24, we have made steady progress 
towards embedding sustainable business practices into the Company. 
We recognise that we are at the start of a long and very important journey 
and look forward to reaching key milestones over the coming years.
At AROA we are focused
on contributing to a 
more sustainable future 
for everybody.
Throughout FY24 we have 
made steady progress 
towards embedding 
sustainable business 
practices into the Company.
	
+ We support the following United Nations Sustainable Development Goals

Annual Report 2024
Our Sustainability Actions
To guide us on our journey, we 
have developed a dashboard to 
measure key sustainability metrics, 
including waste to landfill, water 
usage, wastewater, electricity 
usage, and freight carbon 
emissions. The dashboard helps us 
measure our environmental impact, 
providing data to drive continuous 
improvements in our sustainability 
performance. Over the past 
financial year, we continued to 
collect and analyse this data, 
laying the groundwork for future 
	
+ Environmental Sustainability
development of reduction targets 
for our emissions.
Method Recycling Bins
To encourage good waste disposal 
habits in the workplace, in 
September 2023 we introduced 
centralised communal recycling 
stations containing several waste 
streams to separate landfill from 
paper and recyclable items.
Bike to work
Cycling to work not only has health and fitness benefits but is also an
environmentally sustainable travel method. 
To support and encourage this, in April 2024, AROA set up a bike shed for 
team members to store their bikes safely and securely. In addition to the 
bike shed, we have also purchased bike repair tools and safety vests to 
increase visibility while cycling. 
Cycling to work is gaining popularity, and in 2023, we had 20 of our 
Auckland based team members (around 10%) participate in the Aotearoa 
Bike Challenge.
Some of AROA’s bike to 
work enthusiasts

21
The table below shows the ratio of women to men among our Board members, executives, senior leadership, and 
all employees as at 31 March 2024 across New Zealand and North America.
AROA is te reo Māori for understanding, and with this in mind, we are 
committed to fostering a diverse and inclusive culture across all levels
of the Company. 
Gender diversity
AROA is committed to reaching 
40:40:20 gender representation 
(40% women, 40% men and 20% 
open) by 2033. During 2023 we 
developed the following objectives 
to address gender diversity.
•	 A minimum of 30% gender 
diversity at Senior Leadership 
level by FY26
•	 20% gender diversity at Board 
Level by FY27
	
+ Diversity, Equity and Inclusion
•	 Achieve minimum of 40% 
gender diversity at Manager and 
Supervisor level by FY27
•	 Over the next two years, work 
towards achieving a minimum of 
30% gender diversity in senior 
management by FY26
We will evaluate progress regularly 
and report yearly on this in the 
Annual Report.
Women
Men
Women %
Men %
Board
2
5
29%
71%
Senior Leadership Team
4
10
29%
71%
Supervisors and Managers
16
40
29%
71%
All Employees
139
147
49%
51%
AROA is a proud member 
of Diversity Works, New 
Zealand’s national body
for workplace diversity
and inclusion. 
Employees in
New Zealand
Employees in
North America
 
 
69.7%
Women in Senior
Leadership roles 
29%
Women in our 
Employee Population
49%
Ethnicities Self-identified
by Team Members
20+
287
EMPLOYEES
30.3%

Annual Report 2024
+	 Eid
+	 Diwali
+	 International 
Women’s Day
+	 Lunar New Year
+	 Matariki
+	 Mental Health 
Awareness Week
Celebrating diversity
Since establishing the AROA Women’s 
Network in 2022, the employee-led
committee has worked to foster 
diversity and inclusion through regular 
events and forums. 
In line with our Diversity policy, we 
have created a calendar of key events 
and held regular, well attended 
employee led celebration events 
throughout the year which help to 
foster diversity and inclusion across 
the organisation.
International Women’s Day 
celebrations
Team members 
make pedal powered 
smoothies during 
Mental Health 
Awareness Week
KEY EVENTS

23
Supporting our objective of being a great place to work, AROA offers permanent team members a range of 
employee benefits.
We continue to review employee benefits and look forward to continuing to add to the existing offering.
	
+ People and Culture
Health and Safety
To support the safety and 
wellbeing of our people at AROA, 
in April 2023 we appointed our first 
Health and Safety Advisor. 
Since this appointment, several 
key milestones have been reached. 
These include: the implementation 
of Health and Safety Management 
System, development of a Health 
and Safety intranet site, review and 
enhancement of Health and Safety 
policies, implementation of health 
and safety subcommittees for each 
business area, and the purchase 
and installation of an Automatic 
External defibrillator (AED) at the 
Auckland head office site.
Employee 
Referral 
Programme 
Birthday
Leave 
Employee 
Assistance 
Programme 
(EAP)
Onsite 
gym and 
facilitated 
classes
Remote 
Working 
and Flexible 
Working*
Summer
hours* 
*For eligible roles
*For eligible roles

Annual Report 2024
24
KidzFirst Christmas Party
Every December, Middlemore 
Foundation and BBM Foundation 
team up to give the families of 
more than 200 South Auckland 
children living with long-term 
health conditions a day to 
celebrate with entertainment, 
gifts, and fun. 
Over 600 food parcels and 6000 
gifts were provided at the popular 
community event.
For the second year running, AROA 
was proud to be a key supporter 
of the KidzFirst Christmas party, 
contributing a $10,000 donation 
as well as AROA team members 
volunteering at the event.
	
+ Community
Internship Programme
AROA has a proud history of 
supporting students in the Science 
and Engineering fields, with several 
student placements over the years. 
Since 2022 AROA has run a formal 
internship programme each year, 
spanning 10 weeks. In 2023, 10 
engineering students participated 
in AROA’s internship programme.
“I liked so many things about
my internship at AROA.
The culture is relaxed, and the 
environment is great for learning
– you can approach anyone and
they’re willing to help.”
Victoria Reyes
Fostering interest in STEM careers 
At AROA, we are proud to support initiatives that foster an interest in science, technology, and Engineering (STEM) 
careers. During FY24, AROA developed partnerships with two purpose led organisations focused on encouraging 
interest and participation in STEM careers.
The Wonder Project
The wonder project is Engineering New Zealand’s not-for-profit, free 
programme for schools, designed to inspire young people (rangatahi) 
with STEM. The Wonder Project provides hands on immersive STEM 
learning experiences for school aged children in New Zealand. AROA is 
proud to be a silver sponsor of The Wonder Project.
Robogals
Robogals is a global, student run organisation that aims to inspire and 
empower young women to consider studying engineering and related 
fields by hosting events and workshops. AROA is proud to be a gold 
sponsor of Robogals.


Annual Report 2024
FY24
NZ$000
H2 FY24
NZ$000
H1 FY24
NZ$000
FY23
NZ$000
YoY%
Product sales
67,966
36,780
31,186
60,512
12
Other revenue
1,100
415
685
1,090
1
Total revenue
69,066
37,195
31,871
61,602
12
Gross profit 
58,973
32,165
26,808
51,718
14
Product gross margin %
85%
86%
84%
84%
100 bps
Other income
1,664
694
970
1,734
(4)
Normalised selling and administrative expenses*
(58,968)
(31,486)
(27,482)
(45,132)
31
Research and development
(9,159)
(4,057)
(5,102)
(10,612)
(14)
Total normalised operating expenses
(68,127)
(35,543)
(32,584)
(55,744)
23
Normalised EBIT
(7,490)
(2,684)
(4,806)
(2,292)
236
Add back: depreciation & amortisation
4,395
2,256
2,139
3,834
15
Normalised EBITDA
(3,095)
(428)
(2,667)
1,542
(314)
Normalised net finance income*
1,390
687
703
1,394
-
Normalised loss before income tax
(6,100)
(1,997)
(4,103)
(898)
602
	
+ AROA’s activities and operations
AROA is in the business of soft tissue regeneration. During the year, 
the Group’s principal activity was the development, manufacture and 
distribution of products globally to improve healing in complex wounds 
and soft tissue reconstruction.
Commentary on the Group’s operations and activities during the year is set 
out in the Chair’s Review and CEO’s Report.
	
+ Financial results for the year 
Normalised Profit or Loss
The Directors present their 
report on the Group for
the financial year ended
31 March 2024.
DIRECTORS 
REPORT 
*These items have been normalised by the amounts outlined within the section headed 
‘Reconciliation of Normalised Profit or Loss to NZ GAAP Profit or Loss’.

27
Product Revenue
Product revenue for the year was 
NZ$68.0 million representing
12% growth on the previous 
year (10% in constant currency). 
Myriad performed well, with a 
73% increase to NZ$23.3 million 
(70% on a constant currency 
basis). As expected, although 
TELA Bio’s CY23 sales increased 
by 41%, their focus on inventory 
management measures dampened 
demand for OviTex/OviTex PRS in 
FY24, to deliver product revenue 
of NZ$32.6 million (a 7% and 
8% reduction from FY23, on a 
reported and constant currency 
basis respectively). The overall 
impact of these initiatives was 
confined, as TELA Bio’s demand 
for the products re-aligned with 
their sales in H2 FY24 to deliver 
a 19% increase in OviTex/OviTex 
PRS revenue compared to H1 FY24. 
Endoform sales were in line with 
FY23, with a modest contribution 
from Symphony. 
Ex-USA product revenue continued 
its strong year-on-year growth, 
with a 58% increase on FY23 to 
NZ$2.8 million (FY23 revenue was 
NZ$1.7m, reflecting 60% growth on 
the prior year).
Normalised Other Revenue
Normalised other revenue for the 
year was constant with FY23,2 
at NZ$1.1 million. This represents 
project fee income received for 
product development projects 
undertaken with TELA Bio.
Product Gross Margin %
Full-year product gross margin 
increased by 1%, on both a reported 
and constant currency basis, 
to 85%. This primarily resulted 
from sales growth of AROA’s 
high-margin Myriad products and 
ongoing manufacturing
efficiency improvements. Product 
gross margin increased from 84% 
during H1 FY24 to 86% in H2 FY24.
Other Income
Other income was constant with 
FY23, at ~NZ$1.7 million. This 
comprised of tax credits valued at 
NZ$1.7 million under the Research 
& Development Tax Incentive 
program (compared to NZ$1.6 
million previously).
Normalised Operating Expenses
& EBITDA
Selling and administrative expenses 
were NZ$59.0 million, representing 
a 31% increase from NZ$45.1 million 
in FY23. This was driven by the 
continued expansion of AROA’s 
US-based sales operations, growth 
in aggregate commission payments 
to US sales staff for increased 
Myriad sales, and increased clinical 
development activities. The 
latter reflects a larger investment 
(NZ$3.6 million) into the 
Symphony RCT during FY24 than 
anticipated, due to faster patient 
recruitment. The Symphony RCT 
(n=120) is an 18-month multi-centre 
study assessing the product’s 
efficacy in treating diabetic foot 
ulcers. The data from the study, 
which is expected to be published 
in FY25, will be an important 
catalyst in driving Symphony sales.
Research and development 
expenses were NZ$9.2 million, 
compared to NZ$10.6 million 
in FY23. This was largely due 
to the reduced expenditure on 
the Company’s second platform 
technology (Enivo), decreasing 
from approximately NZ$7 million in 
FY23 to NZ$5 million in FY24. As 
previously communicated, AROA 
has received US Food and Drug 
Administration (FDA) clearance 
for two (of three) components of 
the Enivo system and is engaging 
with the FDA to confirm the design 
of clinical and pre-clinical studies 
to support a further clearance to 
commercialise the Enivo system. 
We will provide a further update on 
this in due course.
The Company capitalised 
NZ$2.8 million of development 
costs in FY24, compared with 
NZ$1.3 million in FY23.3 These 
development costs primarily 
represent investments made into 
existing product line extensions 
and manufacturing process 
improvements, where AROA 
has certainty of the investments 
generating future economic 
benefits. 
The Company generated a 
normalised EBITDA loss of NZ$3.1 
million in FY24, compared to a 
NZ$1.5 million profit in FY23. The 
normalised loss before income 
tax was NZ$6.1 million (NZ GAAP 
Loss before income tax of NZ$10.4 
million) compared to a loss of 
NZ$0.9 million in FY23 (NZ GAAP 
Loss before income tax of NZ$0.4 
million). In the absence of the Enivo 
development investment in FY24, 
AROA would have delivered
a normalised EBITDA profit of 
NZ$1.2 million.
Cashflows
Quarterly cashflows from operating
activities progressed towards 
breakeven during the year, with 
the Company posting positive net 
cash inflows from operations in the 
fourth quarter. On a full-year basis, 
net cash outflows from operating 
activities were NZ$7.4 million 
(compared to previous outflows of 
NZ$3.8 million), resulting from the 
Company’s increased investment 
into its US commercial operations 
and clinical development activities. 
Purchases of property plant 
and equipment reduced from 
NZ$6.0 million in FY23 to NZ$3.5 
million for FY24. This continued 
investment was into additional 
manufacturing capacity which is 
expected to be complete by Q3 
FY25.
Capitalised development costs 
were NZ$2.8 million (compared to 
NZ$1.3 million in FY23) reflecting 
investment into product line 
extensions and manufacturing 
process improvements.
AROA ended FY24 with a strong 
cash balance of NZ$29.5 million, 
compared to NZ$44.7 million as 
at 31 March 2023. The Company 
remains debt-free.

Annual Report 2024
Reconciliation to NZ GAAP profit or loss 
Reported
2024
NZ$000
Reported
2023
NZ$000
Normalised loss before income tax
 
(6,100)
(898)
Other revenue 
-
1,759
Unrealised foreign currency (losses) / gains
(1,146)
1,333
Share based payment expenses
(3,181)
(2,578)
Loss before income tax (NZ GAAP)
 
(10,427)
(384)
Other Revenue 
Other revenue of NZ$1.8 million in 
the prior year represents receipt of 
TELA Bio’s final royalty payment 
to AROA pursuant to the parties’ 
licensing agreement. 
Share Based Payments 
Share based payments is a 
non-cash expense that reflects the 
three-year grant of share options 
	
+ Dividends 
No dividends were paid, declared or recommended during the financial year. 
	
+ Corporate Governance Statement 
AROA recognises the importance of good corporate governance and is committed to ensuring that the business 
maintains a high standard of corporate governance and ethical standards. The Board reviews the Company’s 
policies and governance practices by reference to the Principles of Good Corporate Governance established by 
the ASX Corporate Governance Council. Please refer to AROA’s Corporate Governance Statement (available at 
https://aroa.com/investors) for more information about how the Company’s policies and practices align with these 
principles. 
	
+ Indemnification and insurance of Directors and Officers 
The Company has arranged, as provided for under its Constitution, insurance policies for Directors’ and Officers’ 
liability which, with a deed of indemnity entered into with each director and company secretary, are intended to 
ensure that to the extent permitted by applicable law, the directors and officers will not incur monetary losses as 
a result of actions undertaken by them in that capacity. Certain actions are specifically excluded, for example the 
incurring of penalties and fines which may be imposed in respect of breaches of the law. 
	
+ Director updates 
John Diddams and Dr. Catherine Mohr were re-elected and elected (respectively) as non-executive directors at the 
Company’s annual general meeting on 3 August 2023. 
Steven Engle, the Company’s long-standing non-executive director retired with effect from 31 March 2024, and 
seasoned global commercial operations executive, Darla Hutton, was appointed to the Board from 22 March 2024. 
In accordance with the Board’s rotation policy, John Pinion and Philip McCaw are offering themselves up for 
re-election at the Company’s upcoming annual general meeting on 23 July 2024. Under ASX Listing Rule 14.4, a 
director appointed by the board must not hold office (without election) past the next annual meeting following the 
director’s appointment. Darla Hutton is accordingly also offering herself up for election at that meeting. 
issued to employees between 
July 2020 and March 2024. 
During FY24, NZ$0.5 million in 
prior year share based payments 
expense was reversed through 
retained earnings (2023: $Nil). 
Share based expenses of NZ$0.6 
million incurred during FY24 were 
subsequently reversed through 
retained earnings after 31 March 
2024 (during FY25), as a result of 
performance-based share options 
not vesting to management. 
Unrealised FX Gains 
Unrealised FX gains are non-cash 
(losses) or gains that reflect the 
(loss)/gain on US$ denominated 
transactions that have not been 
completed as at the reporting date. 

29
Name
Board of Directors
Audit Committee
Risk Committee
Remuneration & 
Nomination Committee
Eligible
Attended
Eligible*
Attended
Eligible*
Attended
Eligible*
Attended
Jim McLean 
 10
10
3
3
-
-
-
-
Brian Ward 
10
10
-
3
-
2
-
3
Steve Engle
10
9
-
-
2
1
3
3
Phil McCaw
10
9
-
-
-
-
3
2
John Pinion
10
10
3
2
2
2
-
-
John Diddams
10
8
3
3
-
-
3
3
Dr. Catherine Mohr
10
9
-
-
2
2
-
-
Darla Hutton**
1
1
-
-
-
-
-
-
Description of services 
Fees (NZ$) 
Review of interim consolidated financial statements 
NZ$55,000
	
+ Environmental and social risks
AROA’s manufacturing activities involve the controlled storage, use and disposal of hazardous materials. The 
Company has in place policies and procedures designed to facilitate compliance with applicable environmental 
regulations and to mitigate the risks associated with the Company’s handling of such materials.
	
+ Non-audit services
AROA’s auditor is BDO Auckland. The Group’s statutory audit fee for the financial year ended 31 March 2024 was 
NZ$159,000 (2023:NZ$145,500). 
During the year ended 31 March 2024, BDO Auckland, or entities associated to it, provided the following non-audit 
services to the Group.
The Board is satisfied that the services noted above do not impair BDO’s independence as auditor on the basis 
that such services were not in conflict with BDO’s audit procedures or adequate safeguards were put into place to 
mitigate any independence risks.
	
+ Board and Committee meetings 
The table below shows attendances by each director at Board and Committee meetings during the financial year. 
* To attend as a member of that Committee. Other than to the extent of a conflict of 
interest, the full Board receives a copy of each Committee’s meeting papers and may 
attend all Committee meetings.
** Darla Hutton joined the Board from 22 March 2024
NB: Table above does not include unscheduled calls held during the year.


REMUNERATION 
REPORT

Annual Report 2024
	
+ Overview 
Our remuneration and nomination policies and practices are ultimately 
designed to deliver shareholder value by facilitating and encouraging a 
high level of performance, with AROA’s long-term success in mind. The 
Remuneration & Nomination Committee supports the Board in formulating
and overseeing these policies, with input from external specialists as
appropriate to ensure impartial guidance and expertise.
Remuneration is integral to building a high-growth profitable business, 
and this is reflected in AROA’s approach. Our remuneration framework 
is structured to be competitive within industry, encourage a high level 
of performance and align our people’s interests with those of our 
shareholders. This reinforces AROA’s commitment to excellence and 
achievement and instils a sense of ownership amongst our people, 
fostering a culture of decision-making focused on generating 
shareholder returns.
Our remuneration programme for FY24 comprised of: 
•	 A fixed wage or salary, and legislative superannuation. This is set at 
a level to attract and retain high-calibre employees and is reviewed 
annually taking into account individual, Company and market 
conditions.
•	 A discretionary short-term incentive (STI), providing the potential 
for an annual cash bonus based on pre-determined company and 
individual performance targets. Our STI plans are in place for those at
a senior manager level and above, along with critical specialist roles.
•	 A discretionary long-term incentive (LTI) variable remuneration in 
the form of share options. Our LTI plan applies to our executive and 
senior management teams. We operated two LTI plans in FY24; the NZ 
Option Plan and the US Option Plan. Share options are issued for $nil 
consideration and are not quoted. Each share option entitles the holder 
to subscribe for one fully paid ordinary share in AROA at the specified 
exercise price. An overview of share options granted to the Company’s 
directors during FY24 is provided in the section headed ‘Director 
remuneration details: share based compensation’. For further details 
relating to all share options issued during the year, refer to note 18 to 
the consolidated financial statements.
In accordance with corporate governance best practice, the structure of 
our non-executive director remuneration is separate and distinct from that 
of our CEO and senior leadership. 
The Remuneration & Nomination Committee is focused on ensuring 
that our compensation policies keep pace with the evolving recruitment 
environment, market conditions and our growing size & maturity. 
We undertake remuneration benchmarking exercises both formally, 
through participation in Aon Radford salary surveys, and informally 
through partnerships with recruitment agencies and industry surveys. 
We are continuing to refine our approach to LTI, and from FY25 will 
be conditioning 100% of our Executive Management Team’s LTI on 
performance-based metrics linked to long term financial objectives and 
shareholder returns. We will also be shifting from share options as our sole 
LTI mechanism to a broader range of equity awards, including restricted 
shares and performance share rights. This is reflected in our equity award 
proposals for Darla Hutton, our newest non-executive director, as well as 
for our CEO’s FY25 LTI. These are on the agenda for AROA’s 2024
annual general meeting and will bedetailed in the accompanying Notice 
of Meeting. 
This Remuneration 
Report, which forms part 
of the Directors’ Report, 
outlines our approach 
to remuneration for the 
financial year ended
31 March 2024.

33
	
+ Employee remuneration
This table outlines remuneration 
totalling NZ$100,000 or more 
received by our employees or 
former employees during the 
financial year ended 31 March 
2024. The table includes salary, 
wages and STI annual variable 
remuneration paid during the 2024 
financial year. This does not include 
information for our CEO, who is 
also a director of the Company,
or the share-based expense 
valuation of LTI.
Offshore remuneration amounts 
(including commission paid to
US sales representatives for 
delivering increased Myriad sales) 
have been converted into
New Zealand dollars. 
We had previously extended an 
interest-free loan facility to our 
people (not directors) who had an 
interest in shares issued under a 
legacy employee incentive share 
plan that was wound up prior to 
AROA’s admission to the ASX in 
July 2020. Following updates over 
recent years, the facility was due 
to expire on 28 February 2024. 
However, noting that the loan 
balance was relatively modest 
(~NZ$220,000) and considering 
factors including retention of 
employees, many of whom have 
been with us for more than eight 
years, the Board approved an 
extension of the loan term with 
interest charged of 6% p.a. 
Remuneration range (NZ$)
Number of employees 
100,000 - 110,000
12
110,001 - 120,000
16
120,001 - 130,000
10
130,001 - 140,000
7
140,001 - 150,000
5
150,001 - 160,000
3
160,001 - 170,000
6
170,001 - 180,000
2
180,001 - 190,000
5
190,001 - 200,000
6
200,001 - 210,000
3
210,001 - 220,000
3
220,001 - 230,000
4
230,001 - 240,000
5
240,001 - 250,000
9
250,001 - 260,000
2
260,001 - 270,000
5
290,001 - 300,000
1
300,001 - 310,000
2
320,001 - 330,000
2
330,001 - 340,000
1
340,001 - 350,000
2
350,001 - 360,000
3
360,001 - 370,000
1
370,001 - 380,000
2
380,001 - 390,000
3
400,001 - 410,000
1
420,001 - 430,000
3
440,001 - 450,000
1
530,001 - 540,000
2
540,001 - 550,000
1
570,001 - 580,000
2
580,001 - 590,000
1
600,001 - 610,000
1
610,001 - 620,000
1
630,001 - 640,000
1
640,001 - 650,000
1
660,001 - 670,000
1
670,001 - 680,000
1
720,001 - 730,000
1
770,001 - 780,000
1

Annual Report 2024
	
+ Overview of senior leadership remuneration 
Please refer to the table below for an overview of the remuneration components provided to the Company’s senior 
leadership in FY24.
Component 
Description 
Link to strategy & 
performance 
Fixed remuneration
•	 Base salary
•	 Legislative superannuation
Annual reviews take into 
account individual factors 
such as performance and 
behaviours
STI
•	 At-risk component paid in cash
•	 Designed to remunerate senior leadership relative
to AROA’s performance targets and individual 
performance targets that are aligned with AROA’s
performance objectives
•	 Company performance targets comprise both 
financial and non-financial objectives, including  
revenue, profitability, development, clinical, and 
people metrics
•	 The targets are set at the beginning of each financial 
year and are approved by the Board
•	 Performance against targets is determined by the 
Board at the end of each financial year after review 
by the Remuneration & Nomination Committee
Rewards delivery of
key strategic and 
financial objectives in 
line with AROA’s annual 
business plan. 
LTI
•	 At-risk component in the form of share options
•	 Designed to align senior leadership’s interests with 
shareholder interests over the longer term
•	 Vesting is subject to continued employment (unless 
the Board determines otherwise), so provides a 
longer-term employee benefit
•	 In CY22/23 the Company refined its LTI design 
principles, moving to an annual award structured as 
follows:
•	 50/50 mix (at target value) of service and
performance-based conditions; and 
•	 performance conditions relate to shareholder 
returns (detailed below)
This was reflected in the structure of options provided 
to Brian Ward from FY23, and to senior leadership from 
FY24.
Rewards delivery against 
longer term strategy 
and provides alignment 
between shareholder 
and senior leadership 
outcomes

35
	
+ Overview of CEO remuneration
Brian Ward’s remuneration 
structure is consistent with the 
senior leadership structure outlined 
above. His remuneration target 
and maximum total remuneration 
mix for the 2024 financial year is 
set out in this section. Please refer 
to the remainder of this report 
for further details. Brian does not 
receive additional remuneration in 
his capacity as a director of
the Company or any other
Group company.
Current LTI performance 
conditions 
Considering performance against 
these metrics, all performance 
options scheduled for vesting on 
31 March 2024 will be forfeited. 
This relates to 1,826,330 share 
options, with an aggregate value 
of ~NZ$734,000.
Performance Conditions4
Total % of 
performance options 
eligible to vest
Entry
50+ percentile company TSR 
against a comparator group 
comprising the top 50 (by 
market capitalisation) ASX-listed 
healthcare companies (TSR 
Ranking)
25%
Target
75+ percentile TSR Ranking
50%
Stretch
1. 75+ percentile TSR Ranking;
and
2. Threshold 20-day VWAP as 
at the applicable vesting date. 
These are as follows:
•	 31 March 2024 vesting, 
A$1.50 (112% growth on 31 
March 2022 20-day VWAP)
•	 31 March 2025 vesting, 
A$1.85 (162% growth on 31 
March 2022 20-day VWAP)
•	 31 March 2026 vesting, 
A$2.25 (219% growth on 31 
March 2022 20-day VWAP)
100%
Fixed Remuneration
STI
LTI
Fixed
Remuneration
Target Total
Remuneration
Maximum Total
Remuneration
$0
$200,000.00
$400,000.00
$600,000.00
$800,000.00
$1,000,000.00
$1,200,000.00
$1,400,000.00

Annual Report 2024
	
+ Overview of non-executive director remuneration 
Our non-executive directors receive cash fees, and until FY24, were also granted equity in the form of share 
options. Please refer to the remainder of this report for further details. To maintain objectivity in decision-making, 
we do not offer our non-executive directors performance-based compensation. 
As approved by shareholders last year, the maximum aggregate annual cash-based remuneration payable to all 
our non-executive directors for their services as a director is NZ$750,000. Individual director’s fees are determined 
based on the time commitment and responsibilities of their role, with our Board and Committee Chairs receiving
a higher fee commensurate to their additional workload. Each non-executive director is also entitled to be 
reimbursed for all reasonable travel, accommodation and other expenses they incur for attending AROA meetings 
or on other company business. We do not provide our non-executive directors with superannuation arrangements 
or retirement allowances. 
The Board sees value in promoting share ownership among our non-executive directors as it appropriately aligns 
their interests with those of our shareholders. As noted above, whilst we have until FY24 structured this as share 
options, we are with input from external specialists considering alternative structures and expect to confirm this 
in time for AROA’s 2025 annual general meeting. In the meantime, to ensure parity with the other non-executive 
directors, we are proposing to issue restricted shares to Darla Hutton, our newest Board member (details will be 
included in the Notice of Meeting for our 2024 annual general meeting).
	
+ Director remuneration details
Aggregated
Our directors’ remuneration (in NZ$) for the year ended 31 March 2024 is set out below.
Short term benefits
Post-employment benefits
LTI
Cash salaries 
and fees 
(NZ$)*
STI (NZ$)
Superannuation
(NZ$)
Share based 
payments 
expense** (NZ$)
Total (NZ$)
Jim McLean
$135,000
-
-
$77,194
$212,194
Steven Engle*****
$136,057
-
-
$17,797
$153,854
Philip McCaw
$79,214
-
-
$51,463
$130,677
John Pinion
$136,057
-
-
$51,463
$187,520
John Diddams
$107,894
-
-
$51,463
$159,357
Dr. Catherine Mohr
$111,429
-
-
$66,594
$178,023
Darla Hutton*****
$4,729
-
-
-
$4,729
Brian Ward
$583,440
***$59,618
$22,200
**** $413,361
$1,078,619
TOTAL
$1,293,820
$59,618
$22,200
$729,335
$2,104,973
* Fees for directors who are not based in NZ are fixed in their local currency, and converted 
into NZ$ here for disclosure purposes.
** These amounts reflect the non-cash accounting cost of all share options held by the relevant 
director during the financial year. It includes the cost of share options vesting during the financial 
year and the cost of share options granted during the financial year as approved by shareholders. 
No cash payments are made in relation to these. The amounts are calculated based on NZ IFRS 2 – 
Share-based Payment.
*** Brian Ward achieved 26% against target for AROA’s FY24 performance. He had received 
discretionary annual variable remuneration of NZ$156,555 for AROA’s performance in the previous 
financial year (representing 71% achievement against targets).
**** 625,842 performance-based share options granted to Brian Ward in FY23 did not reach their 
31 March 2024 vesting conditions, so will be forfeited. The share options, with a share-based 
expense valuation of ~NZ$200,000 in FY24, are therefore not included in this table. The options 
were included in Brian’s remuneration disclosure in the 2023 annual report, reflecting a share-
based expense valuation of ~NZ$132,000. Share based expense remuneration of $413,361 in FY24 
includes an amount of ~NZ$192,000 attributable to performance based share options due to vest 
on 31 March 2025 and 2026.
***** Steven Engle retired from the Board at the end of FY24 and Darla Hutton joined the Board 
from 22 March 2024.
NB: Table above does not include reimbursement of reasonable travel, accommodation and other 
expenses incurred by directors for attending AROA meetings or on other company business.

37
	
+ Equity instrument disclosures 
Options holdings
Please see below an overview of the share options held by each director (or their nominee) during the 2024
financial year. Further details regarding the options that vested or which were forfeited, during that year, are 
contained in the subsequent sections of this report.
The table does not include Darla Hutton, who joined the Board from 22 March 2024, and does not hold any
share options.
Share-based compensation
Please see below information on share options issued to our directors during the 2024 financial year. In accordance 
with the requirements of ASX Listing Rule 10.14, the options were issued following shareholder approval received at 
our 2023 annual general meeting.
Balance as at
1 April 2023
Granted as 
compensation
Exercised
Forfeited
Balance at 
the end of the 
year
Vested and 
exercisable
Unvested
Jim McLean
361,329
-
(50,000)
-
311,329
141,943
169,386
Steven Engle*
1,051,620
-
(633,225)
(112,925)
305,470
305,470
-
Philip McCaw
254,545
-
-
-
254,545
141,620
112,925
John Pinion
1,051,620
-
-
-
1,051,620
938,695
112,925
John Diddams
193,072
-
-
-
193,072
80,147
112,925
Dr Catherine Mohr
-
210,686
-
-
210,686
84,259
126,427
Brian Ward
5,708,008
-
-
-
5,708,008
2,418,374
3,289,634
TOTAL
8,620,194
210,686
(683,225)
(112,925)
8,034,730
4,110,508
3,924,222
Effective grant 
date
Number granted
Performance 
hurdle (Y/N)
Exercise price 
per option (A$)
Vesting date
Last exercise 
date
Dr Catherine Mohr
14 November 
2022
84,259
N
$0.87, being 
the volume-
weighted 
average price 
of AROA 
shares on 
the five days 
preceding 
grant
31 March 2024
13 November 
2027
64,311
31 March 2025
62,116
31 March 2026
*In recognition of Steven Engle’s valuable and long-standing contribution to the Company, 
the Board exercised its discretion under the share option plan rules to permit Steven, 
following his retirement from the Board, to retain 305,470 of his share options which had 
already vested. The termination date of these options remains unchanged, so they will 
lapse unless he exercises them prior.

Annual Report 2024
FY24 option vestings
The following share options previously granted to the directors or their nominees vested in the 2024 financial 
year. There is no disclosure for Darla Hutton, who joined the Board from 22 March 2024 and does not hold any 
share options.
FY24 option forfeitures
112,925 share options granted to Steven Engle in CY23 lapsed upon his retirement at the end of the financial year.
As noted in the sub-section headed ‘Current LTI performance conditions’, 625,842 share options issued to Brian 
Ward in FY23 did not meet their 31 March 2024 vesting conditions and will be forfeited.
Shareholdings
The number of ordinary shares in the Company held by each director or their personally related parties during the 
2024 financial year is set out below.
Director
Financial year in which 
granted
Number of
options vested 
Exercise price (A$)
Option expiry
Jim McLean
FY23
89,543
1.083
29 February 2028
Steven Engle
FY23
59,695
1.083
29 February 2028
Philip McCaw
FY23
59,695
1.083
29 February 2028
John Pinion
FY23
59,695
1.083
29 February 2028
John Diddams
FY23
59,695
1.083
29 February 2028
Dr Catherine Mohr
FY24
84,259
0.87
13 Nov 2027
Brian Ward
FY23
330,024
1.165
13 Nov 2027
Director
Financial year in which 
granted
Number of options 
vested 
Exercise price (A$)
Option expiry
Jim McLean5
2,777,108
50,000*
-
2,827,108
Steven Engle
226,553
633,225*
-
859,778
Philip McCaw6 
19,751,154
-
326,000
20,077,154
John Pinion
472,500
-
-
472,500
John Diddams7
1,192,550
-
-
1,192,550
Dr Catherine Mohr
-
-
-
-
Darla Hutton
-
-
-
-
Brian Ward8
33,125,800
-
-
33,125,800
* Shares issued to Jim McLean and Steven Engle upon the exercise of 50,000 share options (exercise price of A$0.75 each) and 633,225 
share options (exercise price of NZ$0.098 each) respectively.  The shares were issued in accordance with the exception under ASX Listing 
Rule 10.16(c) as the share options were issued prior to AROA’s listing on the ASX and the requisite information was disclosed in AROA’s 
IPO Prospectus. 

39
	
+ End of Remuneration Report
This Directors’ Report, incorporating the Remuneration Report, 
is signed in accordance with a resolution of the Board.
Jim McLean
Independent Chair of the Board 


Annual Report 2024
41
For the year ended 31 March 2024
The Directors are responsible for 
the preparation, in accordance with 
New Zealand law and generally 
accepted accounting practice, of 
financial statements which give a 
true and fair view of the financial 
position of the Group as at 31 
March 2024 and the results of their 
operations and cash flows for the 
year ended 31 March 2024.
The Directors consider that 
the consolidated financial 
statements of the Group have 
been prepared using accounting 
policies appropriate to the Group’s 
circumstances, consistently applied 
and supported by reasonable and 
prudent judgments and estimates 
and that all applicable New Zealand 
equivalents to International 
Financial Reporting Standards
have been followed.
The Directors have responsibility 
for ensuring that the proper 
accounting records have been 
kept which enable, with reasonable 
accuracy, the determination of the 
financial position of the Group and 
enables them to ensure that the 
financial statements comply with 
the Financial Reporting Act 2013. 
The Directors have responsibility 
for the maintenance of a system 
of internal control designed to 
provide reasonable assurance as 
to the integrity and reliability of 
financial reporting. The Directors 
consider that adequate steps 
have been taken of safeguard 
the assets of the Group and to 
prevent and detect fraud and 
other irregularities. 
Approved for and on behalf of the 
Board of Directors on 21 May 2024
Jim McLean - Chairman
Brian Ward – CEO
The Directors are pleased 
to present the consolidated 
financial statements of Aroa 
Biosurgery Limited and the 
Group (“Group”) for the year 
ended 31 March 2024. 
DIRECTORS’ 
RESPONSIBILITY 
STATEMENT


INDEPENDENT 
AUDITOR’S
REPORT

Annual Report 2024
 
 
 
 
 
 
BDO Auckland 
INDEPENDENT AUDITOR’S REPORT 
TO THE SHAREHOLDERS OF AROA BIOSURGERY LIMITED 
 
Opinion 
 
We have audited the consolidated financial statements of Aroa Biosurgery Limited (“the Company”) 
and its subsidiaries (together, “the Group”), which comprise the consolidated statement of 
financial position as at 31 March 2024, and the consolidated statement of profit or loss and other 
comprehensive income, consolidated statement of movements in equity and consolidated 
statement of cash flows for the year then ended, and notes to the consolidated financial 
statements, including material accounting policy information. 
 
In our opinion, the accompanying consolidated financial statements present fairly, in all material 
respects, the consolidated financial position of the Group as at 31 March 2024, and its consolidated 
financial performance and its consolidated cash flows for the year then ended in accordance with 
New Zealand equivalents to International Financial Reporting Standards (“NZ IFRS”) and IFRS® 
Accounting Standards. 
 
Basis for Opinion 
 
We conducted our audit in accordance with International Standards on Auditing (New Zealand) 
(“ISAs (NZ)”). Our responsibilities under those standards are further described in the Auditor’s 
Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We 
are independent of the Group in accordance with Professional and Ethical Standard 1 International 
Code of Ethics for Assurance Practitioners (including International Independence Standards) (New 
Zealand) issued by the New Zealand Auditing and Assurance Standards Board, and we have fulfilled 
our other ethical responsibilities in accordance with these requirements. We believe that the audit 
evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 
 
Other than in our capacity as auditor we have no relationship with, or interests in, the Company or 
any of its subsidiaries. 
 
Key Audit Matters 
 
Key audit matters are those matters that, in our professional judgement, were of most significance 
in our audit of the consolidated financial statements of the current period. These matters were 
addressed in the context of our audit of the consolidated financial statements as a whole, and in 
forming our opinion thereon, and we do not provide a separate opinion on these matters. 
 
Recognition of revenue – TELA Bio revenue share 
Key Audit Matter 
  
How The Matter Was Addressed in Our Audit 
The Group's largest customer is TELA Bio who is 
the Group’s sales and distribution partner for 
abdominal wall reconstruction, hernia repair 
and breast reconstruction in North America and 
Europe. The contract with TELA Bio entitles 
the Group to an agreed percentage of TELA 
Bio’s net sales. This revenue is considered to 
be variable consideration (“revenue share”). 
The consideration is variable since the 
quantum of TELA Bio’s inventory that is 
eventually sold and the price that it is sold at, 
are uncertain. 
• 
We evaluated Management’s revenue 
recognition policy based on our 
understanding of the contract with 
TELA Bio and the requirements of NZ 
IFRS15 - Revenue from contracts with 
customers. 
• 
We obtained Management’s 
calculations and accounting paper 
prepared for the revenue share accrual 
and evaluated the reasonableness of 
key inputs and assumptions. The key 
inputs included sales history, revenue 

45
 
 
 
 
 
BDO Auckland 
Recognition of revenue – TELA Bio revenue share 
 
Key Audit Matter 
  
How The Matter Was Addressed in Our Audit 
 
Variable consideration to be recognised is 
estimated by using the expected value method. 
The estimation is based on information that is 
reasonably available to the Group which 
incorporates key factors including sales history, 
forecast revenue growth, expiry date of 
inventory held, and average selling prices 
achieved by TELA Bio. The amount of variable 
consideration is only recorded by the Group to 
the extent that it is highly probable that a 
significant reversal in the amount of the 
cumulative revenue recognised will not occur 
when the uncertainty associated with the 
variable consideration is subsequently 
resolved. During the year ended 31 March  
2024, Management changed their accounting 
estimate for the TELA Bio revenue share by 
revising the assumptions disclosed in Note 2 
Summary of significant accounting policies of 
the consolidated financial statements.    
 
We consider this to be a key audit matter 
because of the judgement involved in 
determining the variable consideration and the 
quantum of the accrued revenue of $15.14m. 
 
Refer to Note 2 Summary of significant 
accounting policies – change in accounting 
estimates and Note 3 Revenue and segment 
information of the consolidated financial 
statements.    
      
growth factors, expiry dates of 
inventory held, and average selling 
prices achieved by TELA Bio. 
• 
We obtained confirmation from TELA 
Bio, confirming their stock holding, 
sales history and the actual revenue 
share for their sales made in the year 
ended 31 March 2024. 
• 
We compared the key inputs and 
assumptions with those used by 
Management last year and considered 
if these are indicative of Management 
bias. 
• 
We considered if the amount of 
variable consideration estimated is 
only recorded by the Group to the 
extent that it is highly probable that a 
significant reversal in the amount of 
the cumulative revenue recognised will 
not occur. 
• 
We reviewed the disclosures in Notes 2 
and 3 to the consolidated financial 
statements, including the revenue 
recognition policy, to the requirements 
of the accounting standard.   
 
Intangible assets impairment assessment
 
Key Audit Matter 
 
How The Matter Was Addressed in Our Audit 
 
The Group has recognised goodwill, customer 
relationships and reacquired rights intangible 
assets on a historical acquisition.  The goodwill 
of $5.54m, customer relationships of $1.85m 
and reacquired rights of $6.52m at 31 March 
2024 are subject to an annual impairment test 
in accordance with NZ IAS 36 - Impairment of 
Assets. 
 
Management performed their impairment test, 
by considering the recoverable amount of the 
Cash Generating Unit (‘CGU’) (to which the 
intangible assets are allocated) using a value in 
use calculation. This calculation is complex and 
subject to key inputs and assumptions such as 
• 
We obtained an understanding of key 
controls relating to the review and 
approval of the impairment review. 
• 
We obtained Management’s 
impairment assessment including the 
value in use calculation prepared for 
the CGU. We evaluated and challenged 
the key inputs and assumptions. The 
key inputs included revenue growth 
rates, terminal growth rate, gross 
margins and discount rate.  
• 
We assessed the accuracy of previous 
forecasts to actual performance to 
form a view on the reliability of 

Annual Report 2024
 
 
 
 
 
 
BDO Auckland 
Intangible assets impairment assessment
 
Key Audit Matter 
 
How The Matter Was Addressed in Our Audit 
 
discount rates and future cash flows, which 
inherently include a degree of estimation 
uncertainty and are prone to potential bias and 
inconsistent application and therefore 
considered to be a key audit matter. 
 
Refer to Note 12 Intangible assets of the 
consolidated financial statements. 
Management's forecasting ability and to 
understand key differences between 
historical actual versus forecast 
performance.  
• 
We engaged our internal valuation 
experts to assess the methodology used 
by Management in their value in use 
calculation is in accordance with NZ 
IAS 36 - Impairment of Assets, the 
accuracy of the model and to assess 
the terminal growth rate and discount 
rate based on our expert’s market and 
valuation knowledge. 
• 
We reviewed Management's sensitivity 
analysis performed on key inputs and 
assumptions to determine the extent to 
which any changes would affect the 
recoverable amount of the CGU. We 
also considered and tested alternative 
sensitivities. 
• 
We compared the carrying value of the 
CGU to the recoverable amount 
determined by the value in use 
calculation to identify any impairment 
losses. 
• 
We reviewed the disclosures in Note 12 
to the consolidated financial 
statements, including impairment and 
sensitivity analysis, to the 
requirements of the accounting 
standard. 
 
 
Share-based payment arrangements 
 
Key Audit Matter 
 
How The Matter Was Addressed in Our Audit 
The Group issued options to certain employees, 
including Directors, under the share-based 
payment arrangements during the year ended 
31 March 2024. The share-based payment 
arrangements included both market based and 
non-market based vesting conditions.  In 
determining the value of the new 
arrangements, the Group used the services of a 
third-party valuation specialist. 
 
The Group also had existing share-based 
payment arrangements that were exercised 
and forfeited during the year. 
 
• 
We evaluated Management’s 
assessment on the treatment of the 
share-based payment arrangements in 
accordance with NZ IFRS 2 – Share-
based Payment. 
• 
We agreed the terms of the share-
based payment arrangements issued 
during the year to offer letters and 
rules of the share option plan. 
• 
We assessed, in conjunction with our 
internal valuation experts, the 
appropriateness of the valuation 
methodology used by Management's 

47
 
 
 
 
 
BDO Auckland 
Share-based payment arrangements 
Key Audit Matter 
 
How The Matter Was Addressed in Our Audit
There is judgement involved in determining the 
value of share-based payment arrangements 
and subsequent recording of the fair value as 
an expense over the estimated vesting period. 
As a result and given the magnitude of the 
expense in the current year, the audit of the 
share-based payment arrangements was 
considered a key audit matter. 
 
The share-based payments expense recorded 
for the year ended 31 March 2024 is $3.40m 
resulting in a share-based reserve of $10.27m 
as at 31 March 2024. Details of these share-
based payment arrangements are disclosed in 
Note 4 Employee benefit expenses and Note 18 
Share based payments reserve of the 
consolidated financial statements. 
specialist and the key input 
assumptions such as volatility rates, 
expected life and probability of 
achieving the market-based 
performance conditions. 
• 
We assessed the Group's judgements i
relation to the probability of achievin
non-market based vesting conditions. 
• 
We recalculated the share-based 
payments expense recorded in the 
profit or loss over the relevant vesting
periods. 
• 
We reviewed the disclosures in Note 4
and 18 in relation to the share-based 
payment arrangements to the 
requirements of the accounting 
standard. 
 
Capitalisation of internally generated intangible assets
Key Audit Matter 
 
How The Matter Was Addressed in Our Audit
The Group has recognised internal 
development costs of $2.82m as an intangible 
asset during the year ended 31 March 2024. 
 
The Group incurs significant expenditure in 
researching and developing medical devices for 
wound and soft tissue repair. The Group 
capitalises expenditure incurred in the 
development of products and processes when 
certain criteria are met as disclosed in Note 12 
to the consolidated financial statements. Costs 
that do not meet the criteria for capitalisation 
are expensed to profit or loss as incurred. 
 
There is judgement involved in determining 
whether expenditure incurred can be 
capitalised as an intangible asset and the costs 
directly attributable to create, produce, and 
prepare the asset to be capable of operating in 
the manner intended by management.  
 
We consider this to be a key audit matter 
because of the judgement involved in 
determining expenditure able to be capitalised  
and the quantum of the amount of the amount 
capitalised of $2.82m. 
 
Refer to Note 12 intangible assets of the 
consolidated financial statements. 
• 
We evaluated Management’s 
assessment on the treatment of the 
capitalised development costs in 
accordance with NZ IAS 38 - Intangibl
Assets to determine if they met the 
recognition criteria. 
• 
We assessed whether expenditure 
capitalised was directly attributable t
creating, producing, and preparing th
asset to be capable of operating in th
manner intended by Management. 
• 
We agreed a sample of costs 
capitalised to appropriate supporting 
documentation. 
• 
We reviewed the disclosures in Note 1
in relation to the internally generated
intangible assets to the requirements 
of the accounting standard. 
 
 
 
 

Annual Report 2024
 
 
 
 
 
 
BDO Auckland 
Other Information  
 
The directors are responsible for the other information. The other information comprises the Aroa 
Biosurgery FY24 Results and FY25 Outlook, and Appendix 4E – ASX Listing Rule 4.2A (but does not 
include the consolidated financial statements and our auditor’s report thereon) which we obtained 
prior to the date of this auditors report, and the Annual report, which is expected to be made 
available to us after that date.  
 
Our opinion on the consolidated financial statements does not cover the other information and we 
do not express any form of audit opinion or assurance conclusion thereon. 
 
In connection with our audit of the consolidated financial statements, our responsibility is to read 
the other information and, in doing so, consider whether the other information is materially 
inconsistent with the consolidated financial statements, or our knowledge obtained in the audit or 
otherwise appears to be materially misstated. If, based on the work we have performed, we 
conclude that there is a material misstatement of this other information, we are required to report 
that fact. 
 
If, based on the work we have performed on the other information that we obtained prior to the 
date of this auditor’s report, we conclude that there is a material misstatement of this other 
information, we are required to report that fact. We have nothing to report in this regard. 
 
When we read the annual report (but does not include the consolidated financial statements and 
our auditor’s report thereon), if we conclude that there is a material misstatement therein, we are 
required to communicate the matter to the directors. 
 
Directors’ Responsibilities for the Consolidated Financial Statements 
 
The directors are responsible on behalf of the Group for the preparation and fair presentation of 
the consolidated financial statements in accordance with NZ IFRS and IFRS Accounting Standards, 
and for such internal control as the directors determine is necessary to enable the preparation of 
consolidated financial statements that are free from material misstatement, whether due to fraud 
or error. 
 
In preparing the consolidated financial statements, the directors are responsible on behalf of the 
Group for assessing the Group’s ability to continue as a going concern, disclosing, as applicable, 
matters related to going concern and using the going concern basis of accounting unless the 
directors either intend to liquidate the Group or to cease operations, or have no realistic 
alternative but to do so. 
 
Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements  
 
Our objectives are to obtain reasonable assurance about whether the consolidated financial 
statements as a whole are free from material misstatement, whether due to fraud or error, and to 
issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of 
assurance, but is not a guarantee that an audit conducted in accordance with ISAs (NZ) will always 
detect a material misstatement when it exists. Misstatements can arise from fraud or error and are 
considered material if, individually or in the aggregate, they could reasonably be expected to 
influence the decisions of users taken on the basis of these consolidated financial statements. 
 
A further description of our responsibilities for the audit of the financial statements is located at 
the External Reporting Board’s website at: https://www.xrb.govt.nz/assurance-standards/auditors-
responsibilities/audit-report-1/.  
 

49
 
 
 
 
 
 
BDO Auckland 
This description forms part of our auditor’s report. 
 
Who we Report to  
 
This report is made solely to the Company’s shareholders, as a body. Our audit work has been 
undertaken so that we might state those matters which we are required to state to them in an 
auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept 
or assume responsibility to anyone other than the Company and the Company’s shareholders, as a 
body, for our audit work, for this report or for the opinions we have formed. 
 
The engagement partner on the audit resulting in this independent auditor’s report is Blair Stanley. 
 
 
 
BDO Auckland 
Auckland  
New Zealand 
21 May 2024 
 
 
 


For the year ended 31 March 2024
CONSOLIDATED 
FINANCIAL 
STATEMENTS

Annual Report 2024
Consolidated Statement of Profit or Loss and other 
Comprehensive Income
For the year ended 31 March 2024
The above consolidated statement of profit or loss and other comprehensive income should be 
read in conjunction with the accompanying notes.
Note
2024
$000
2023
$000
Revenue
3
69,066
63,360
Cost of sales
(10,093)
(9,884)
Gross profit 
58,973 
53,476 
Other income
3
1,664 
1,734 
Selling and administrative expenses
(62,149)
(47,709)
Research and development expenses
(9,159)
(10,612)
Loss from operations before net financing income
4
(10,671)
(3,111)
Finance income
5
2,002 
3,111 
Finance expenses
5
(1,758)
(384)
Net finance income
244
2,727
Loss before income tax
(10,427)
(384)
Income tax expense
6
(201)
(12)
Loss for the year attributable to shareholders
(10,628)
(396)
Other comprehensive income
Items that will or may be reclassified to profit or loss
Exchange gain / (loss) arising on translation of foreign operations
836
(1,328)
Items that will or may be reclassified to profit or loss
Changes in the fair value of equity investments at fair value through other 
comprehensive income
8
(557)
21
Total other comprehensive income /(loss)
279
(1,307)
Total comprehensive loss for the year attributable to shareholders
(10,349)
(1,703)
Earnings per share during the year:
Basic earnings per share (cents)
19
(3.09)
(0.12)
Diluted earnings per share (cents)
19
(3.09)
(0.12)

53
Note
2024
$000
2023
$000
Current assets
Cash and cash equivalents
7
11,522
9,540
Term deposits
7
18,000
35,134
Derivative assets
-
192
Trade and other receivables
9
13,437
14,329
Inventories
10
8,104
4,831
Prepayments
1,816
1,439
Contract assets
3(a)
15,140
11,071
Tax receivable
313
339
Financial assets at fair value through other comprehensive income 
8
703
1,260
Total current assets
69,035
78,135
Non-current assets
 
 
Property, plant, and equipment
11
15,769 
14,234 
Prepayments
104 
126 
Right of use assets
15
6,447 
6,403 
Intangible assets
12
19,702 
17,623 
Total non-current assets
42,022
38,386
Total assets
111,057
116,521
Current liabilities
 
 
Trade and other payables
13
3,741 
3,607 
Derivative liabilities
1,061
Employee benefits
14
3,708
3,745 
Lease liabilities 
16
1,004
559
Total current liabilities
9,514
7,911
 
 
 
 
 
Non-current liabilities
 
 
Provisions 
174 
171 
Lease liabilities
16
6,431
6,548
Total non-current liabilities
6,605
6,719
 
Total liabilities
16,119
14,630
 
Net assets
94,938
101,891
 
 
 
 
Equity
 
 
 
Share capital
17
146,798 
146,491 
Accumulated losses
(62,152)
(51,524)
Foreign currency translation reserve
(679) 
(1,515) 
Equity investment reserve
8
703
1,260
Share based payment reserve
18
10,268 
7,179 
Total equity
94,938
101,891
Consolidated Statement of Financial Position 
As at 31 March 2024
The above consolidated statement
of financial position should be read in 
conjunction with the accompanying notes.
On behalf of the Board 21 May 2024
Jim McLean - Chairman
Brian Ward – CEO

Annual Report 2024
Note
Share 
Capital
$000
Accumu-
lated 
Losses
$000
Foreign 
Currency 
Transla-
tion 
Reserve
$000
Equity 
Invest-
ment 
Reserve
$000
Share 
Based 
Payments 
Reserve
$000
Total 
Equity
$000
Balance as at 1 April 2023
146,491
(51,524)
(1,515)
1,260
7,179
101,891 
Comprehensive income
 
 
 
 
Loss for the year
-
(10,628)
-
-
-
(10,628)
Other comprehensive income for 
the year
-
-
836
(557)
-
279 
Total comprehensive income for 
the year
-
(10,628)
836
(557) 
-
(10,349)
Transactions with shareholders
 
 
 
 
Share based payment expenses
18
 
-
 -
-
3,404
3,404
Forfeiture of unvested employee 
share options 
18
-
-
-
-
(223)
(223)
Employee shares exercised
17/18
196
-
-
-
(92)
104
Issue of shares to employees 
17
111
-
-
-
-
111
Total transactions with shareholders
307 
-
-
-
3,089
3,396
 
 
 
 
 
Balance as at 31 March 2024
146,798 
(62,152)
(679)
703 
10,268 
94,938
Balance as at 1 April 2022
145,755
(51,128)
(187)
1,239
4,812
100,491 
Comprehensive income
 
 
 
 
Loss for the year
-
(396)
-
-
-
(396)
Other comprehensive income for 
the year
-
-
(1,328)
21
-
(1,307) 
Total comprehensive income for 
the year
-
(396)
(1,328)
21 
-
(1,703)
Transactions with shareholders
 
 
 
 
Share based payment expenses
18
-
-
 -
-
2,676
2,676
Forfeiture of unvested employee share 
options 
18
-
-
-
-
(98)
(98)
Employee shares exercised
17/18
564
-
-
-
(211)
353
Issue of shares to employees 
17
172
-
 -
-
-
172
Total transactions with shareholders
736 
-
-
-
2,367
3,103
Balance as at 31 March 2023
146,491
(51,524)
(1,515)
1,260
7,179
101,891
Consolidated Statement of Movements In Equity
For the year ended 31 March 2024
The above consolidated statement of movements in equity should be read 
in conjunction with the accompanying notes.

55
Consolidated Statement of Cash Flows
For the year ended 31 March 2024
The above consolidated statement of cash flows should be read 
in conjunction with the accompanying notes.
Note: The Group has term deposits of $18,000,000 as at the reporting date (2023: $35,134,000). In line with NZ IAS 7 Statement of Cash Flows, term 
deposit with an initial maturity of more than three months does not become part of cash and cash equivalent and are therefore excluded in the cash 
and cash equivalent position in the statement of cash flows (refer to note 7). 
Note
2024
$000
2023
$000
Cash flows from operating activities
 
Cash receipts from sales of goods
65,247
52,408
Cash receipts from grant income, project fees, and license fees
2,763
4,167
Cash paid to suppliers and employees
(76,831)
(60,952)
Interest received
1,726
1,170
Dividend received
1
-
Interest paid
(10)
-
Income tax paid
(271)
(565)
Net cash outflow from operating activities
24a
(7,375)
(3,772)
 
 
 
Cash flows from investing activities
 
 
Purchase of property, plant and equipment
11
(3,523)
(6,029)
Purchase of intangible assets
12
(644)
(250)
Capitalised development costs
12
(2,818)
(1,332)
Proceeds from term deposits
7
17,134
14,866
Net cash inflow from investing activities
10,149
7,255
 
Cash flows from financing activities
 
 
Proceeds from issue of options 
 
85
348
Proceeds from issue of shares 
111
172
Lease liability – principal payments
16
(740)
(645)
Lease liability – interest payments
16
(490)
(379)
Net cash outflow from financing activities
 
(1,034)
(504)
Net increase in cash and cash equivalents
1,740
2,979
Effect of exchange rate fluctuations on cash and cash equivalents
242
396
Cash and cash equivalents at beginning of year
9,540
6,165
Cash and cash equivalents at end of year
7
11,522
9,540


For the year ended 31 March 2024
NOTES TO THE 
CONSOLIDATED 
FINANCIAL 
STATEMENTS

Annual Report 2024
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
1.	
Corporate Information 
Aroa Biosurgery Limited (“the Company”) together with its subsidiaries (the “Group”) is a leading soft tissue 
regeneration company which develops, manufactures and sells medical devices for wound and soft tissue 
repair using its proprietary extracellular matrix (ECM) technology.
The Company is a limited liability company incorporated and domiciled in New Zealand. The address of its 
registered office is 64 Richard Pearse Drive, Airport Oaks, Auckland. 
The consolidated financial statements of Aroa Biosurgery Limited and its subsidiaries (the “Group”) for the 
year ended 31 March 2024 comprise the Company and its two subsidiaries, Aroa Biosurgery Incorporated and 
Mesynthes Nominee Limited. All subsidiary entities have a reporting date of 31 March.
2.	
Summary of significant accounting policies 
Statement of compliance and basis of preparation
The consolidated financial statements have been prepared in accordance with New Zealand Generally 
Accepted Accounting Practice (“NZ GAAP”). They comply with New Zealand equivalents to International 
Financial Reporting Standards (“NZ IFRS”), other New Zealand accounting standards and authoritative 
notices that are applicable to entities that apply NZ IFRS, as appropriate for profit orientated entities. The 
consolidated financial statements also comply with International Financial Reporting Standards (“IFRS”).
Basis of measurement
The consolidated financial statements have been prepared on the historical cost basis, except for the 
following item (refer to individual accounting policies for details):
	
–
Financial assets at fair value through other comprehensive income
	
–
Derivative assets at fair value through profit or loss
Functional and presentation currency
The consolidated financial statements are presented in New Zealand dollars ($) which is the Company’s 
functional and Group’s presentation currency. All financial information is presented in New Zealand dollars 
rounded to the nearest thousands, except where otherwise indicated.
Use of estimates and judgements
The preparation of the consolidated financial statements in conformity with NZ IFRS requires management 
to make judgements, estimates and assumptions that affect the application of accounting policies and the 
reported amounts of assets, liabilities, income and expenses. Actual results may differ from those estimates.
Significant estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting 
estimates are recognised in the period in which the estimates are revised and in any future periods affected.
Estimates and judgements were made in respect of:
	
–
TELA Bio Incorporated (“TELA Bio”) accrued revenue (refer to notes 3 and “Change in accounting 
estimates - Tela Bio Accrued Revenue”, as discussed below)
	
–
research and development tax incentive accrual (refer to note 3)
Equity holding
Principal Activity
Place of 
Business
2024
%
2023
%
Aroa Biosurgery Incorporated 
Sales & Distribution
US
100 
100 
Mesynthes Nominee Limited
Nominee Shareholder
NZ
100 
100 
Aroa Biosurgery Incorporated is a subsidiary of Aroa Biosurgery Limited and is incorporated and domiciled 
in the United States. The address of its registered office is 9155 Brown Deer Road #2, San Diego, California 
92121. Mesynthes Nominee Limited is a subsidiary of Aroa Biosurgery Limited and is incorporated and 
domiciled in New Zealand. The address of its registered office is 64 Richard Pearse Drive, Airport Oaks, 
Auckland.
The consolidated financial statements have been prepared in accordance with the requirements of the 
Financial Reporting Act 2013 and the Companies Act 1993. These consolidated financial statements were 
authorised for issue by the Board of Directors on 21 May 2024.

59
	
–
the likely term of leased premises, which impacts leasehold improvements assets and right of use assets 
capitalised (refer to notes 11, 15 and 16)
	
–
impairment assessment of intangible assets (refer to note 12)
	
–
the value of development expenditure capitalised (refer to note 12)
	
–
the value of share-based payments (refer to note 18)
Change in accounting estimates - Tela Bio accrued revenue 
As disclosed in note 3 (a), TELA Bio is the Group’s largest customer and sales and distribution partner for 
abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. The 
contract with TELA Bio entitles the Group to an agreed percentage of TELA Bio’s net sales. 
The consideration from TELA Bio is received from a transfer price for the products shipped to TELA Bio, with 
the balance of the consideration received on a quarterly true up to the agreed percentage based on TELA 
Bio’s net sales. Using the expected value method, the Group estimates the true up on TELA Bio’s inventory 
at the reporting date considering the expected sale of those products by TELA Bio. Having considered TELA 
Bio’s revenue guidance for calendar year 2024, the Group updated certain assumptions such as forecast 
revenue growth and expiry date of inventory held used in calculating the accrued revenue for the current 
period. 
The change in accounting estimates has resulted in a recognition of $3,561,000 in incremental accrued 
revenue in the current year. In accordance with NZ IAS 8 Accounting Policies, Changes in Accounting 
Estimates and Errors, the change in accounting estimate is recognised prospectively by including it in profit 
or loss in the financial year ended 31 March 2024. 
Change in accounting estimates – Inventory valuation 
During the year, the Company changed the allocation of overhead to inventory from hours-based cost driver 
to freeze-dried weight-based cost driver method, reflecting more accurate method of allocating overhead 
to inventory. The change in accounting estimates has resulted in an increase of inventory value by $928,000 
with the corresponding credit in the cost of goods sold. In accordance with NZ IAS 8 Accounting Policies, 
Changes in Accounting Estimates and Errors, the change in accounting estimate is recognised prospectively 
by including it in profit or loss in the financial year ended 31 March 2024.
Going concern
The Group posted a net loss before tax of $10,427,000 for the year (2023: $384,000 loss). The Group posted 
total operating cash outflow of $6,856,000 (2023: outflow of $3,772,000). 
The Directors have continued to apply the going concern assumption as the basis of the preparation of the 
consolidated financial statements. 
In reaching their conclusion that the going concern assumption is appropriate, the Directors have considered 
the ability to achieve financial performance and cash flow forecasts prepared by management, and the 
sufficiency of the cash on hand as at the reporting date. 
Principles of consolidation
The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of the Group as 
at the reporting date and the results of all subsidiaries for the year then ended.
Subsidiaries are all entities (including structured entities) over which the Group has control. The Group 
controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with 
the entity and has the ability to affect those returns through its power over the entity.
Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are 
deconsolidated from the date that control ceases.
Intercompany transactions and balances and unrealised gains on transactions between Group companies are 
eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment 
of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure 
consistency with the policies adopted by the Group.
New standards, interpretations and amendments not yet effective
There are no new standards, amendments or interpretations that have been adopted or are not yet effective 
that have a material impact on the Group except for the below standards:
	
–
Disclosure of Accounting Policies (Amendments to NZ IAS 1 Presentation of Financial Statements and 
IFRS Practice Statement 2 Making Materiality Judgements)
The amendments aim to make accounting policy disclosures more informative by replacing the 
requirement to disclosure “significant accounting policies” with “material” accounting policy information”. 

Annual Report 2024
3.	
Revenue and segment information 
The Group is in the business of developing, manufacturing and selling soft tissue repair products. Revenue 
from contracts with customers is recognised when performance obligations pursuant to that contract are 
satisfied by the Group. 
The Group has identified the following main categories of revenue:
Sales of goods
The Group’s revenue primarily consists of the sale of its products. Revenue is recorded when the customer 
takes possession of the product. All contracts with customers are standardised and satisfy the criteria 
of transaction approval, identification of each party’s rights, payment terms, commercial substance, and 
probable collection based on the customer’s ability and intention to pay. Revenue is recognised at a point in 
time when control over the product transfers to the customer, which is assessed to be at the time of receipt 
of goods by the customer. 
The Group also sells its products via a distributor model whereby the sales are made direct to a distributor 
being the customer of the Group, with the distributor permitted to resell the Aroa products to an end user. 
The Group has assessed these arrangements to consider that control passes to the distributor at the point the 
distributor takes possession of the products. The Group considers itself to be acting as principal in the sale of 
goods to distributors and recognise revenue on a gross basis. 
All contracts with distributors are standardised and satisfy the criteria of transaction approval, identification 
of each party’s rights, payment terms, commercial substance, and probable collection based on the 
customer’s ability and intention to pay. Revenue is recognised at a point in time when control over the 
product transfers to the distributor as the customer, which is assessed to be at the time of receipt of goods 
by the distributor. 
a.	 Revenue share: The Group’s largest customer is TELA Bio who is the Group’s sales and distribution partner 
for abdominal wall reconstruction and hernia repair and breast reconstruction in North America and Europe. 
The contract with TELA Bio entitles the Group to an agreed percentage of TELA Bio’s net sales. This revenue 
is considered to be variable consideration (“revenue share”). The consideration is variable since the quantum 
of TELA Bio’s inventory that is eventually sold and the price that it is sold at are uncertain.
The consideration from TELA Bio is received from a transfer price for the products shipped to TELA Bio, with 
the balance of the consideration received on quarterly true up to the agreed percentage based on TELA 
Bio’s net sales. The Group estimates the true up on TELA Bio’s inventory at the reporting date by using the 
expected value method. The estimation is based on information that is reasonably available to the Group 
which incorporates key factors including sales history, forecast revenue growth, expiry date of inventory held 
and average selling prices achieved by TELA Bio. The amount of variable consideration estimated is only 
recorded by the Group to the extent that it is highly probable that a significant amount of the cumulative 
revenue recognised will be received in the future. Amount receivable from Tela Bio at 31 March 2024 in 
relation to revenue share $15,140,000 (2023:$11,071,000), refer to note 2. 
b.	 Project fees: Project fees received are recognised over time using the input method when the 
performance obligations are fulfilled pursuant to the project development agreement. The Company’s input 
methods include resources consumed, labour hours expensed and costs incurred. Any project fees received, 
for which the requirements under the project agreement have not been completed, are carried as income in 
advance (liability) until all applicable performance obligations have been fulfilled. 
c.	 Royalties: Royalty payment represents the payments received from TELA Bio upon achievement of 
cumulative net sales of the products in European territory. Royalty payments are recognised in the statement 
of profit or loss at a point in time upon completion of the performance obligation.
The amendments also provide guidance under what circumstance, the accounting policy information is 
likely to be considered material and therefore requiring disclosure. 
	
–
Definition of Accounting Estimates (Amendments to NZ IAS 8 Accounting Policies, Changes in 
Accounting Estimates and Errors)
The amendments to NZ IAS 8, which added the definition of accounting estimates, clarify that the effects 
of a change in an input or measurement technique are changes in accounting estimates, unless resulting 
from the correction of prior period errors. These amendments clarify how entities make the distinction 
between changes in accounting estimate, changes in accounting policy and prior period errors.
	
–
International Tax Reform – Pillar Two Model Rules (Amendment to IAS 12 Income Taxes)
These amendments had no effect on the consolidated financial statements of the Group.

61
2024
$000
2023
$000
Sales of goods (USA)
65,190
58,783
Sales of goods (Rest of the world)
2,776
1,729
Royalties (USA)
-
1,758
Project fees (USA)
1,100
1,090 
Total revenue
69,066
63,360
Revenue recognised point in time
67,966
62,270
Revenue recognised over time 
1,100
1,090
Total revenue 
69,066
63,360
Segment information
Revenues from external customers are from sales of goods and project fees as reflected above. 
The Group sells its products and services to external customers who are largely located in the United States 
of America (the “USA”) as reflected in the sales above.
For the purpose of the internal reporting provided to the chief operating decision makers, business activities, 
performances and any associated assets and liabilities are reviewed as a consolidated group.
Revenues of $33,746,000 (2023: $37,898,000) are derived from a single external customer, being sales of 
products and services to TELA Bio, which is the Group’s sales and distribution partner. 
The Group held all of its non-current assets in New Zealand with an exception of the right-of-use assets of 
$455,000 (2023: $550,000) for the leasehold property and property, plant and equipment of $209,000 
(2023: $134,000) in the USA as of the reporting date.
Other income
4.	
Loss from operations before net financing income 
2024
$000
2023
$000
Research and development tax credit income 
1,628
1,673
Other income 
36
61
Balance at end of the year
1,664
1,734
Loss from operations before net financing income includes the following:
Note
2024
$000
2023
$000
Auditor’s fee:
Statutory audit – BDO
163
135
Half-year review – BDO 
55
55
Employee benefit expenses
45,137
37,158
Employer contributions defined contribution Superannuation scheme 
2,632
1,929
Employee share-based payment expenses 
18
3,404
2,578
Depreciation:
 
 
Leasehold improvements 
11
550
505
Plant and equipment
11
906
900
Furniture and fittings
11
72
64
Computer equipment
11
460
329
Right and use assets
15
1,024
807
Directors' fees (excluding share based payment expenses)
20
710
492
Insurance 
1,462
1,187
Amortisation:
Patents 
12
126
74
Customer relationships
12
618
619
Reacquired rights
12
543
542
Capitalised development costs
12
96
-

Annual Report 2024
5. 	 Net finance income 
Finance income and finance expenses have been accrued to the reporting date using the effective
interest method.
6. 	 Income taxes 
Tax expense comprises current and deferred tax. Current tax and deferred tax is recognised in profit or loss 
except to the extent that it relates to a business combination, or items recognised directly in equity or in 
other comprehensive income.
Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax 
rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of 
previous years. Current tax includes any tax liability arising from the declaration of dividends.
Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and 
liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not 
recognised for:
	
–
temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business 
combination and that affects neither accounting nor taxable profit or loss; and
	
–
temporary differences arising on the initial recognition of goodwill; 
Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they 
reverse, using tax rates enacted or substantively enacted at the reporting date.
In determining the amount of current and deferred tax the Group takes into account the impact of uncertain 
tax positions and whether additional taxes and interest may be due. The Group believes that its accruals 
for tax liabilities are adequate for all open tax years based on its assessment of many factors, including 
interpretations of tax law and prior experience. This assessment relies on estimates and assumptions and 
may involve a series of judgements about future events. New information may become available that causes 
the Group to change its judgement regarding the adequacy of existing tax liabilities; such changes to tax 
liabilities will impact tax expense in the period that such a determination is made.
Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities 
and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or 
on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax 
assets and liabilities will be realised simultaneously.
A deferred tax asset is recognised for unused tax losses, tax credits and deductible temporary differences, 
to the extent that it is probable that future taxable profits will be available against which they can be utilised. 
Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer 
probable that the related tax benefit will be realised, such reductions are reversed when the probability of 
future taxable profits improves.
2024
$000
2023
$000
Finance income 
Interest received on bank balances – financial assets at amortised cost
1,800
1,315
Other finance income
Foreign currency gains
94
463
Unrealised foreign currency gains on derivatives
-
192
Unrealised foreign currency gains
108
1,141
Total finance income
2,002
3,111
Finance expenses 
 
Interest expenses – lease liabilities (Note 16)
(490)
(378)
Other finance expenses
 
Finance costs – make good provision
(14)
(6)
Unrealised foreign currency losses on derivatives
(1,254)
-
Total finance expenses
(1,758)
(384)
Net finance income
244
2,727

63
Income tax recognised in profit or loss and other comprehensive income
Major components of tax expense
As at 31 March 2024, the Company has used all brought forward tax losses (2023: losses carried forward of 
$4,604,581). Utilisation of these tax losses is dependent upon the Group meeting the continuity of ownership 
provisions of the Income Tax Act 2007 and carrying forward and offsetting the net losses against net taxable 
income earned in subsequent years by the Group.
The Group has elected to defer expenditure relating to research and development allowed under section 
DB34 of the Income Tax Act 2007. As at 31 March 2024, the Group had $33,193,250 (2023: $25,524,916)
of expenditure available to offset against subsequent years income subject to section EJ23 of the Income
Tax Act 2007.
Deferred tax assets have been recognised to the extent they offset deferred tax liabilities. No deferred tax has 
been recognised on tax losses or deferred research and development expenditure in 2024 on the basis that 
large tax profits are not foreseeable in the year ending 31 March 2025. Total tax effected deferred tax asset 
not recognised at 31 March 2024 $9,752,000 (2023: $5,650,000).
Reconciliation of income tax expense
2024
$000
2023
$000
Accounting loss before income tax
(10,427)
(384)
Income tax @ 28%
(2,920)
(108)
Impact of tax rates in overseas jurisdictions 
(329)
(70)
Expenses not deductible for tax purposes
76
278
Tax credits received subject to tax
(21)
(84)
Income not subject to tax
-
(420)
Prior year tax over provisions 
(51)
(211)
Recognition deferred tax on temporary differences and tax losses
3,446
627
Income tax expense
201
12
2024
$000
2023
$000
Current tax expense
 
 
Current period 
201
12
R&D tax credit
-
-
Total current tax benefit
-
-
Deferred tax (income)
-
 -
Total tax expense
201
12
2024
$000
2023
$000
Deferred tax assets/(liabilities) recognised
 
 
Accrued revenue 
(4,239)
(3,100)
Deferred R&D expenditure
5,642 
5,425 
Intangible assets
(2,316)
(2,993)
Rights of use assets 
(1,678)
(1,639)
Lease liabilities
1,947
1,834
Other temporary differences
13
81
Provision 
631
392
Total deferred tax asset/(liability) recognised
-
-
2024
$000
2023
$000
Deferred tax assets unrecognised (tax effected) 
 
 
Temporary differences
6,335
1,722
Deferred R&D expenditure
3,417
2,639
Unused tax losses
-
1,289
Total deferred tax asset unrecognised (tax effected)
9,752
5,650

Annual Report 2024
7.	
Cash and cash equivalents & term deposits
Cash and cash equivalents include cash on hand, deposits held at call with financial institutions and other 
short term deposits with maturities of three months or less and bank overdrafts.
8.	
Financial assets at fair value through other comprehensive income
The Group classifies the following financial assets at fair value through other comprehensive income 
(“FVTOCI”): Equity investments in relation to the USA listed equity securities for Group’s investment in TELA 
Bio for which the Group has elected to recognise fair value gains or losses through other comprehensive 
income. TELA Bio is the Group’s largest customer and trading partner where the investment is held on a long 
term basis. The Group held 74,316 (2023: 74,316 shares) shares at a value of US$5.67 per share as at 
the reporting date (2023: US$10.64).
Financial assets measured at FVTOCI include the following:
The fair value of the listed equity securities is based on published market price (level 1 in the fair value 
hierarchy) and is revalued at reporting date.
9.	
Trade and other receivables
Trade and other receivables are recognised initially at fair value plus directly attributable transaction 
costs and subsequently measured at amortised cost using the effective interest method less provision for 
impairment. 
The Group applies the NZ IFRS 9 simplified approach to measuring expected credit losses using a lifetime 
expected credit loss provision for trade receivables. To measure expected credit losses on a collective basis, 
trade receivables are grouped based on similar credit risk and aging. The expected loss rates are based 
on the Group’s historical credit losses experienced over the three-year period prior to the period end. The 
historical loss rates are then adjusted for current and forward-looking information on macroeconomic
factors affecting the Group’s customers.
During the year, the Group entered into short-term deposit arrangements with BNZ and Westpac. The term 
deposits not yet matured as of the reporting date had an average rate of 6.05% (2023: 4.96%) per annum 
with a maturity of 3-12 months from the reporting date. 
2024
$000
2023
$000
Bank balances
11,522
9,540
Total cash and cash equivalents
11,522
9,540
2024
$000
2023
$000
US listed equity securities 
Balance at beginning of the year
1,260
1,239
Changes in fair value through other comprehensive income
(557)
21
Balance at end of the year
703
1,260
2024
$000
2023
$000
Trade receivables
11,446
12,225
Less: Provision for impairment of trade receivables
(309)
(580)
Net trade receivables 
11,137
11,645
Other receivables
433
947
Other receivables – Research and Development Tax Incentive accrual 
1,693
1,500
Trade and other receivables
13,263
14,092
GST receivable
174
237
Total current trade and other receivables
13,437
14,329
2024
$000
2023
$000
Term deposits
18,000
35,134
Total term deposits
18,000
35,134

65
10.	 Inventories 
Inventories are measured at the lower of cost and net realisable value. The cost of inventories is based on 
the standard cost principle, and includes expenditure incurred in acquiring the inventories, production or 
conversion costs and other costs incurred in bringing them to their existing location and condition. In the 
case of manufactured inventories and work in progress, cost includes an appropriate share of production 
overheads based on normal operating capacity.
Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs 
of completion and costs to sell. An inventory provision is created to reflect instances where the product is 
expected to expire before being sold
11.	 Property, plant & equipment 
(i) Recognition and measurement: Items of plant and equipment are measured at cost less accumulated
depreciation and accumulated impairment losses. 
Purchased software that is integral to the functionality of the related equipment is capitalised as part of that 
equipment.
When parts of an item of property, plant and equipment have different useful lives, they are accounted for as 
separate items (major components) of property, plant and equipment.
Any gain or loss on disposal of an item of property, plant and equipment (calculated as the difference 
between the net proceeds from disposal and the carrying amount of the item) is recognised in profit or loss.
(ii) Subsequent expenditure: Subsequent expenditure is capitalised only if it is probable that the future
economic benefits associated with the expenditure will flow to the Group.
(iii) Depreciation: For plant and equipment, depreciation is based on the cost of an asset less its residual
value. Where significant components of individual assets that have a useful life that is different from the
remainder of those assets, those components are depreciated separately.
Trade receivables amounting to $11,137,000 (2023: $11,645,000) are shown net of impairment losses. 
Provisions have been made appropriately. Trade receivables are interest free. Trade receivables of a short-
term duration are not discounted. Other receivables include an accrual of tax credit income relating to the 
Research and Development Tax Incentive program. 
(i) Impaired receivables
As at 31 March 2024, current trade receivables with a nominal value of $309,000 (2023: $580,000) were 
impaired and provided for.
(ii) Past due but not impaired receivables
As at 31 March 2024, trade receivables of $2,140,000 (2023: $3,733,000) were past due but not impaired. 
Subsequent to the reporting date, the Group received over $1,372,000 of these past due trade receivables. 
The ageing analysis of trade receivables is as follows:
2024
$000
2023
$000
Current
8,997
7,912 
1 - 30 days overdue
1,286
2,545 
30 - 60 days overdue
377
309
60 - 90 days overdue 
246
234
90 + days overdue
540
1,225
Total trade receivables
11,446
12,225
2024
$000
2023
$000
Raw materials
2,475
1,911
Work in progress
4,178
2,191
Finished goods
2,050
938
Provision for obsolescence
(599)
(209)
Total inventories
8,104
4,831

Annual Report 2024
Depreciation is recognised in profit or loss on a straight-line basis over the estimated useful lives of each 
component of an item of property, plant and equipment. Assets under construction are not subject to 
depreciation.
The useful life estimate for the current year of significant items of property, plant and equipment are as 
follows:
Depreciation methods, rates and residual values are reviewed at reporting date and adjusted if appropriate.
(iv) Capital commitment
Please refer to note 24e for capital commitments.
Leasehold 
Improve-
ments
$000
Capital Work 
In Progress
$000
Plant and 
Equip-ment 
$000
Fixture & 
Fitting
$000
Computer 
Equipment & 
Software
$000
Total
$000
Cost 
 
 
 
 
 
Balance 1 April 2022
1,631
4,165
8,566
624
1,287
16,273
Additions
46
4,889
397
152
533
6,017
Transfers in/ (out)
2,941
(3,328)
373
13
1
-
Disposals
-
-
(14)
-
-
(14)
Balance 31 March 2023
4,618
5,726
9,322
789
1,821
22,276
Accumulated Depreciation
Balance 1 April 2022
(1,076)
-
(4,204)
(256)
(714)
(6,250)
Depreciation
(505)
-
(900)
(64)
(329)
(1,798)
Disposals
-
-
6
-
-
6
Balance 31 March 2023
(1,581)
-
(5,098)
(320)
(1,043)
(8,042)
Net Book Value
Balance 1 April 2022
555
4,165
4,362
368
573
10,023
Balance 31 March 2023
3,037 
5,726
4,224
469
778
14,234
Leasehold 
Improve-
ments
$000
Capital Work 
In Progress
$000
Plant and 
Equipment 
$000
Fixture & 
Fitting
$000
Computer 
Equipment & 
Software
$000
Total
$000
Cost 
Balance 1 April 2023
4,618
5,726
9,322
789
1,821
22,276
Additions
9
2,978
277
16
243
3,523
Transfers in/(out)
248
(380)
132
-
-
-
Disposals
-
-
-
-
-
-
Balance 31 March 2024
4,875
8,324
9,731
805
2,064
25,799
Accumulated Depreciation
Balance 1 April 2023
(1,581)
-
(5,098)
(320)
(1,043)
(8,042)
Depreciation
(550)
-
(906)
(72)
(460)
(1,988)
Disposals
-
-
-
-
-
-
Balance 31 March 2024
(2,131)
-
(6,004)
(392)
(1,503)
(10,030)
Net Book Value
Balance 1 April 2023
3,037
5,726
4,224
469
778
14,234
Balance 31 March 2024
2,744
8,324
3,727
413
561
15,769
Leasehold improvements	
15 years
Fixtures & fittings	
3 - 10 years
Plant & equipment	
5-10 years
Computer equipment & software	
3 years

67
12.	 Intangible assets
Patents that are acquired by the Group and have finite useful lives are measured at cost less accumulated 
amortisation and accumulated impairment losses. Subsequent expenditure is capitalised only when 
it increases the future economic benefits embodied in the specific asset to which it relates. All other 
expenditure is recognised in profit or loss as incurred.
Trademarks have finite useful lives and are measured at cost less accumulated amortisation and accumulated 
impairment losses. 
Patent and trademark costs are amortised on a straight-line basis over the useful life. 
Goodwill, customer relationships and reacquired rights are attributable to the purchase of the wound care 
business entered into between the Group and Hollister Incorporated. Goodwill is not amortised. 
Impairment tests on goodwill and other intangible assets with indefinite useful economic lives are undertaken 
annually at the financial year end. Other non-financial assets are subject to impairment tests whenever events 
or changes in circumstances indicate that their carrying amount may not be recoverable. Where the carrying 
value of an asset exceeds its recoverable amount (i.e. the higher of value in use and fair value less costs to 
sell), the asset is written down accordingly.
Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is 
carried out on the smallest group of assets to which it belongs for which there are separately identifiable cash 
flows; its cash generating units (“CGUs”). Goodwill is allocated on initial recognition to each of the Group’s 
CGUs that are expected to benefit from a business combination that gives rise to the goodwill. 
Impairment charges are included in profit or loss. An impairment loss recognised for goodwill is not reversed.
Customer relationships and reacquired rights are amortised on a straight-line basis in profit or loss over their 
estimated useful lives, from the date that they are available for use.
The estimated useful lives for the current period are as follows:
Patents and trademarks
3-21 years
Customer relationships 
9 years
Reacquired rights
18 years
Capitalised development costs*
 5 years
*The Group commences the amortisation when the asset is completed. 
Amortisation methods, rates and residual values are reviewed at reporting date and adjusted if appropriate.
Research costs are expensed as incurred. Costs associated with maintaining product development are 
recognised as an expense as incurred. Costs that are directly associated with the production of identifiable 
and unique product developments controlled by the Group, and that will probably generate economic 
benefits exceeding costs beyond one year, are recognised as intangible assets where the following criteria are 
met:
	
–
it is technically feasible to complete asset so that it will be available for use;
	
–
management intends to complete the asset and use or sell it;
	
–
there is an ability to use or sell the asset;
	
–
it can be demonstrated how the asset will generate probable future economic benefits;
	
–
adequate technical, financial and other resources to complete the development and to use or sell it; and
	
–
the expenditure attributable to the asset during its development can be reliably measured.
Other development expenditures that do not meet these criteria are expensed when incurred. Development 
costs previously recognised as expenses are not recognised as assets in a subsequent period. Development 
costs that have a finite useful life that have been capitalised are amortised from the commencement of the 
time at which they are available for use on a straight-line basis over the period of its expected benefit, not 
exceeding five years. 
Capitalised development costs are carried at cost less accumulated amortisation and impairment losses. 
Capitalised development costs are amortised over the periods the Group expects to benefit from utilising the 
products. The amortisation expense is included within selling and administrative expenses in profit or loss.

Annual Report 2024
12.	 Intangible assets (continued)
On 31 March 2024, the Group tested whether goodwill has suffered any impairment. For the purpose of 
impairment testing, goodwill is allocated to the Group’s Wound Care business, at which goodwill is monitored 
for internal management purposes. 
The recoverable amount is determined based on value in use calculations using the method of estimating 
future cash flows and determining a discount rate in order to calculate the present value of the cash flows.
Patents & 
trademarks
$000
Customer 
relationships
$000
Reacquired 
rights
$000
Goodwill
$000
Capitalised 
development 
costs
$000
Total
$000
Cost 
 
 
 
 
 
Balance 1 April 2023
1,611
5,563
9,772
5,538
1,332
23,816
Additions
644
-
-
-
2,818
3,462
Balance 31 March 2024
2,255
5,563
9,772
5,538
4,150
27,278
 
Accumulated Depreciation
Balance 1 April 2023
(388)
(3,091)
(2,714)
-
-
(6,193)
Amortisation
(126)
(618)
(543)
-
(96)
(1,383)
Balance 31 March 2024
(514)
(3,709)
(3,257)
-
(96)
(7,576)
Net Book Value
Balance 1 April 2023
1,223
2,472
7,058
5,538
1,332
17,623
Balance 31 March 2024
1,741 
1,854
6,515
5,538
4,054
19,702
Patents & 
trademarks
$000
Customer 
relationships
$000
Reacquired 
rights
$000
Goodwill
$000
Capitalised 
development 
costs
$000
Total
$000
Cost 
 
 
 
 
 
Balance 1 April 2022
1,354
5,563
9,772
5,538
-
22,227
Additions
257
-
-
-
1,332
1,589
Balance 31 March 2023
1,611
5,563
9,772
5,538
1,332
23,816
Accumulated Depreciation
Balance 1 April 2022
(314)
(2,472)
(2,172)
-
-
(4,958)
Amortisation
(74)
(619)
(542)
-
-
(1,235)
Balance 31 March 2023
(388)
(3,091)
(2,714)
-
-
(6,193)
Net Book Value
Balance 1 April 2022
1,040
3,091
7,600
5,538
-
17,269
Balance 31 March 2023
1,223 
2,472
7,058
5,538
1,332
17,623

69
No impairment was identified for the Wound Care business as a result of this review, nor under any 
reasonable possible change, in any of the key assumptions described above.
2024
2023
Discount rate post tax
10.6%
10.1%
Terminal growth rate
3.5%
3.5%
Average growth rates over the forecast period 
25.8%
34.4%
Average gross profit over the forecast period 
89%
88%
Basis of key assumptions
	
–
Cash flow projections
The cashflow projections used in the recoverable amount calculations are based on management’s budget 
for the year ending 31 March 2025, then applicable growth rates applied to revenue and costs from year 
2-5. Management has used its past experience of revenue growth, operating costs, margin and external 
sources of information where appropriate to determine their expectations for the future. 
	
–
Growth rates 
The growth rates reflect the long-term average growth rates for the product lines and health care industry 
(publicly available). 
	
–
Discount rates
The present value of the expected cash flows is determined by applying a suitable discount rate. The 
discount rate was derived based on the weighted average cost of capital (WACC) for comparable entities 
in the healthcare industry, based on market data. The discount rates reflect appropriate adjustments 
relating to market risk.
13.	 Trade and other payables
Trade and other payables are initially recognised at fair value plus directly attributable transaction costs 
and subsequently at amortised cost. Trade and other payables represent liabilities for goods and services 
provided to the Group prior to the end of financial year which are unpaid.
Trade payables generally have terms of 30 days and are interest free. Trade payables of a short-term duration 
are not discounted.
14.	 Employee benefits
(i) Short term employee benefits
Liabilities for wages and salaries, including non-monetary benefits and accumulating annual leave that is 
expected to be settled wholly within 12 months after the end of the period in which the employees render the 
related service are recognised in respect of employees’ services up to the end of the reporting period and are 
measured at the amounts expected to be paid when the liabilities are settled.
The obligations are presented as other payables and accruals in the statement of financial position if the 
entity does not have an unconditional right to defer settlement for at least 12 months after the reporting date, 
regardless of when the actual settlement is expected to occur.
(ii) Defined contribution plans
Obligations for contributions to defined contribution plans are expensed as the related service is provided.
2024
$000
2023
$000
Trade payables
1,709
1,909
Accrued expenses
2,032
1,693
Other payables
-
5
Total trade and other payables
3,741
3,607
2024
$000
2023
$000
Leave and wages accrual 
2,512
1,864
Bonus accrual 
1,196
1,881
Employee benefits 
3,708
3,745
A discounted cash flow (“DCF”) model has been based on five-year forecast cash flow projections. The key 
assumptions used in calculating the recoverable amount are as follows:

Annual Report 2024
15.	 Right of use assets
16.	 Lease liabilities
All leases are accounted for by recognising a right-of-use asset and a lease liability except for: 
	
–
Leases of low value assets; and 
	
–
Leases with a term of 12 months or less
Lease liabilities are measured at the present value of the contractual payments due to the lessor over the 
lease term, with the discount rate determined by reference to the rate inherent in the lease unless (as is 
typically the case) this is not readily determinable, in which case the Group’s incremental borrowing rate on 
commencement of the lease is used. Variable lease payments are only included in the measurement of the 
lease liability if they are dependent on an index or rate. In such cases, the initial measurement of the lease 
liability assumes the variable element will remain unchanged throughout the lease term. Other variable lease 
payments are expensed in the period to which they relate.
On initial recognition, the carrying value of the lease liability may also include: 
	
–
amounts expected to be payable under any residual value guarantee; 
	
–
the exercise price of any purchase option granted in favour of the Group if it is reasonably certain to 
exercise that option; and
	
–
any penalties payable for terminating the lease, if the term of the lease has been estimated on the basis 
of termination option being exercised. 
Right of use assets are initially measured at the amount of the lease liability, reduced for any lease incentives 
received, and increased for:
	
–
lease payments made at or before commencement of the lease; 
	
–
initial direct costs incurred; and 
	
–
the amount of any provision recognised where the Group is contractually required to dismantle, 
remove or restore the leased asset. 
Subsequent to initial measurement, lease liabilities increase as a result of interest charged at a constant rate 
on the balance outstanding and are reduced for lease payments made. Right-of-use assets are amortised on 
a straight-line basis over the remaining term of the lease or over the remaining economic life of the asset if, 
rarely, this is judged to be shorter than the lease term.
When the Group revises its estimate of the term of any lease (because, for example, it re-assesses the 
probability of a lessee extension or termination option being exercised), it adjusts the carrying amount of 
2024 
Properties Total
$000
2023
Properties Total
$000
Balance at beginning of the year
6,403
5,333
Additions during the year
1,068
1,844
Depreciation for the year 
(1,024)
(807)
Modification adjustment
-
33
Balance at end of the year
6,447
6,403
2024 
Properties Total
$000
2023
Properties Total
$000
Balance at beginning of the year
7,107
5,876
Additions during the year
1,068
1,844
Interest expense
490
378
Lease payments
(1,230)
(1,024)
Modification adjustment
-
33
Balance at end of the year
7,435
7,107
Current
1,004
559
Non-current
6,431
6,548
Total
7,435
7,107

71
2024 
$000
2023
$000
Share capital at beginning of the year
146,491
145,755
Shares exercised under share option plan 
196
564
Issue of shares to employees 
111
172
Share capital at end of the year
146,798
146,491
# of shares
Ordinary
shares 2024
Ordinary
shares 2023
At beginning of year
343,109,468
342,461,133
Issue of share capital
1,098,366
648,335
At end of year
344,207,834
343,109,468
the lease liability to reflect the payments to make over the revised term, which are discounted at a revised 
discount rate. The carrying value of lease liabilities is similarly revised when the variable element of future 
lease payments dependent on a rate or index is revised. In both cases an equivalent adjustment is made 
to the carrying value of the right-of-use asset, with the revised carrying amount being amortised over the 
remaining (revised) lease term.
When the Group renegotiates the contractual terms of a lease with the lessor, the accounting depends on 
the nature of the modification:
	
–
if the renegotiation results in one or more additional assets being leased for an amount commensurate 
with the standalone price for the additional rights-of-use obtained, the modification is accounted for as 
a separate lease in accordance with the above policy
	
–
in all other cases where the renegotiated increases the scope of the lease (whether that is an extension 
to the lease term, or one or more additional assets being leased), the lease liability is remeasured using 
the discount rate applicable on the modification date, with the right-of-use asset being adjusted by the 
same amount 
	
–
if the renegotiation results in a decrease in the scope of the lease, both the carrying amount of the lease 
liability and right-of-use asset are reduced by the same proportion to reflect the partial or full termination 
of the lease with any difference recognised in profit or loss. The lease liability is then further adjusted to 
ensure its carrying amount reflects the amount of the renegotiated payments over the renegotiated term, 
with the modified lease payments discounted at the rate applicable on the modification date. The right-of-
use asset is adjusted by the same amount. 
For contracts that both convey a right to the Group to use an identified asset and require services to be 
provided to the Group by the lessor, the Group has elected to account for the entire contract as a lease, i.e. it 
does allocate any amount of the contractual payments to, and account separately for, any services provided 
by the supplier as part of the contract. 
Nature of leasing activities (in the capacity as lessee)
The Group leases three properties in the jurisdictions in which it operates. In some jurisdictions it is customary 
for lease contracts to provide for payments to increase each year by inflation and in others to be reset 
periodically to market rental rates. The Group also leases certain items of plant and equipment.
As standard industry practice, the Group’s property leases are subject to market rent reviews. A 1% increase in 
these payments would result an additional $12,000 outflow compared to the current period’s cash outflow of 
$1,230,000 (2023: $1,024,000). 
Please refer to note 21 for lease maturity analysis
17.	 Share capital
Ordinary shares
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares 
and share options are recognised as a deduction from equity, net of any tax effects. These ordinary shares 
have no par value.

Annual Report 2024
18.	 Share based payments reserve 
Share option plan
The Group operates a share option plan for selected employees to provide an opportunity to participate in a 
Share Option Plan. This is an offer of options to acquire ordinary shares. Under the terms of the plan, a parcel 
of options was issued to employees with an exercise price equal to the market valuation of shares at the time 
of offer. The grant of share options is split into three tranches vesting over a three year period. 
The share based payments reserve comprises the fair value of the employee share purchase plan before its 
classifications to share capital upon settlement.
The grant date fair value of equity-settled share-based payment awards granted to employees is recognised 
as an employee expense, with a corresponding increase in equity, over the period that the employees 
unconditionally become entitled to the awards. The amount recognised as an expense is adjusted to reflect 
the number of awards for which the related service and non-market performance conditions are expected 
to be met, such that the amount ultimately recognised as an expense is based on the number of awards 
that do meet the related service and non-market performance conditions at the vesting date. For share-
based payment awards with non-vesting conditions, the grant date fair value of the share-based payment 
is measured to reflect such conditions and there is no true-up for differences between expected and actual 
outcomes.
Key valuation assumptions for the share option plan are:
a) Aroa Biosurgery share option plan (the “Option Plan”) – prior to IPO
Under the Option Plan prior to IPO, the Company granted directors, key management and certain employees, 
options to subscribe for ordinary shares since 2017.
Grant Date
6 October 2023
Performance
6 October 2023 
Non-Performance
3 August 
2023
1 August 
2022
14 November 
2022
Share price at grant 
date (AUD)
0.819
0.755
0.910
0.775
0.930
Valuation date
6 October
2023
6 October
2023
4 August
2023
1 March
2023
14 November 
2022
Share price at valuation 
date (AUD)
0.76
0.76
0.90
1.10
0.93
Average exercise price 
(NZD)
0.97
0.97
0.92
0.64
0.94
Expected volatility*
72%
72%
69%
72%
75%
Expected life 
5 years
5 years
5 years 
5 years 
5 years
Risk free factor
3.98%-4.06%
4.10%
3.90%
3.55%
3.24%
Valuation model
Monte Carlo
Binomial
Binomial
Binomial
Binomial
Dividend yield
0%
0%
0%
0%
0%
2024 
$000
2023
$000
Balance as at 1 April 
7,179
4,812 
Share based payment expense
3,404
2,676
Employee shares forfeited
(223)
(98)
Total expenses recognised in consolidated statement of profit or loss
3,181
2,578
Employee shares exercised 
(92)
(211)
Balance as at 31 March
10,268
7,179

73
b) Aroa Biosurgery share option plan (the “Option Plan”) – on and after IPO
On the Group’s IPO in July 2020, the share options were issued to certain employees and directors under 
a new share option plan. Under this plan, the Group continue to issue options to certain employees and 
directors. 
Grants under the Option Plan comprised 25,348,855 (2023: 17,828,074) share options with various vesting 
conditions including non-market service conditions, market conditions and non-market performance 
conditions.
Summary of options granted under the Option Plan – prior to IPO
Share options outstanding at the end of the year have the following expiry dates:
2024 Average 
exercise price 
per option
2024
# of options
2023 Average 
exercise price 
per option NZ$
2023 
# of options
Opening balance 
0.10
2,841,450
0.10
3,085,200
Exercised during the period
0.10
(1,105,725)
0.10
(243,750)
Closing balance
0.10
1,735,725
0.10
2,841,450
Vested and exercised as at 31 March 
0.10
1,735,725
0.10
2,841,450
2024 Average 
exercise price 
per option NZ$
2024
# of options
2023 Average 
exercise price 
per option NZ$
2023 
# of options
Opening balance 
1.09
17,828,074
1.07
12,901,575
Granted in August 2022
-
-
0.64
3,545,344
Granted in November 2022
0.93
50,000
0.94
2,093,580
Granted in August 2023
0.93
210,686
-
-
Granted in October 2023
0.97
8,978,601
-
-
Exercised during the year
0.81
(50,000)
1.23
(435,758)
Forfeited during the period
1.06
(1,668,506)
1.21
(276,667)
Closing balance
0.78
25,348,855
1.09
17,828,074
Vested and exercised as at 31 March 
1.09
11,919,471
1.22
8,964,193
Grant date
Expiry date
Share options
2024
Share options
2023
1 October 2018
01 October 2028
790,725
1,339,900
1 July 2019
01 October 2028
-
228,750
1 December 2019
30 November 2029
945,000
1,272,800
Total
1,735,725
2,841,450

Annual Report 2024
Share options – on and after IPO outstanding at the end of the year have the following expiry dates:
Grant date
Expiry date
Share options
2024
Share options
2023
24 July 2020
23 July 2025
4,885,950
4,935,950
29 September 2020
28 September 2025
1,538,200
1,683,200
22 April 2021
31 March 2026
200,000
200,000
28 June 2021
28 June 2026
2,005,000
2,295,000
9 August 2021
8 August 2026
2,925,000
3,075,000
1 August 2022
29 February 2028
3,432,419
3,545,344
14 November 2022
13 November 2027
1,712,515
2,093,580
3 August 2023
13 November 2027
210,686
-
6 October 2023
30 June 2024 - 3 August 
2028
8,439,085
-
Total
25,348,855
17,828,074
19.	 Earnings per share
Earnings per share has been calculated based on shares and share options issued at the respective 
measurement dates.
2024
‘000
2023
‘000
Numerator
Loss for the year after tax (“N”) in $000
(10,628)
(396)
Denominator
Weighted average number of ordinary shares used in basic EPS (“D1”) 
343,825
342,917
Effects of:
Employee share options *
24,049
18,673
Weighted average number of shares used in diluted EPS (“D2”)
343,825
342,917
Cents
Cents
Basic earnings per share (N/D1 x 100)
(3.09)
(0.12)
Diluted earnings per share (N/D2 x 100)
(3.09)
(0.12)
*As employee share options are anti-dilutive, these were not included in the calculation of diluted earnings per share above.

75
20.	 Related parties
(i) Subsidiaries 
Interests in subsidiaries are set out in Note 1.
(ii) Key management compensation
Key management includes Directors (Executive and Non-Executive) and the executive management team. 
Executive Management Team
2024
$000
2023
$000
Short term employee benefits
2,239
2,421
Share based payment expenses
1,254
609
Total
3,493
3,030
Non-executive Directors
2024
$000
2023
$000
Short term employee benefits
710
492
Share based payment expenses
316
262
Total
1,026
754
(iii) Year end balances
There were no related party balance at year end other than loans provided to key management personnel for 
acquisition of Company shares prior to IPO of $92,000 (2023: $117,000).
(iv) Transactions with related parties
There were no other related party transactions during the year. 
21.	 Financial risk management
The Group’s activities expose it to a variety of financial risks: market risk (including currency risk and 
interest rate risk), credit risk and liquidity risk. The Group’s overall risk management programme focuses on 
the unpredictability of financial markets and seeks to minimise potential adverse effects on the financial 
performance of the Group. The Group uses different methods to measure different types of risk to which it 
is exposed. These methods include sensitivity analysis in the case of interest rate and foreign exchange risks 
and aging analysis for credit risk.
Market risk
Market risk is the risk that changes in market prices, such as foreign exchange rates and interest rates, will 
affect the Group’s income or the value of its holdings of financial instruments. The objective of market risk 
management is to manage and control risk exposures within acceptable parameters whilst optimising the 
return on risk.
Foreign exchange risk
The Group is exposed to currency risk on sales, purchases and liabilities that are denominated in a currency 
other than the respective functional currency of the Company, being NZ dollars (NZD). The currency risk 
arises primarily with respect to sales and expenses. 
The Group has certain net monetary assets/(liabilities) that are exposed to foreign currency risk. The table 
below summarises the Group’s net exposure at reporting date to foreign currency risk, against its respective 
functional currency, expressed in NZ dollars.

Annual Report 2024
Exposure to foreign currency risk 
2024
USD
$000
AUD
$000
EUR
$000
CAD
$000
Cash and cash equivalents 
1,446
-
-
-
Trade and other receivables
6,763
-
68
31
Financial assets at FVTOCI
421
-
-
-
Trade and other payables 
(3,796)
(30)
(1)
(4)
Lease liabilities
(289)
-
-
-
Derivatives
27,150
-
-
-
Net exposure
31,695
(30)
67
27
2023
USD
$000
AUD
$000
EUR
$000
Cash and cash equivalents
3,199
-
-
Trade and other receivables
7,683
-
19
Financial assets at FVTOCI
791
-
-
Trade and other payables 
(796)
(24)
-
Lease liabilities
(351)
-
-
Derivatives
22,650
-
-
Net Exposure
33,176
(24)
19
Sensitivity analysis – underlying exposures
A 5% weakening/strengthening of the NZ dollar against the US dollar at 31 March 2024 would have increased/
decreased equity and the net result for the period by the amounts shown below. Based on historical 
movements a 5% increase or decrease in the NZ dollar is considered to be a reasonable estimate. This analysis 
assumes that all other variables remain constant.
US dollar
The Group’s net result and equity for the period would have been $2,784,000 higher on a 5% weakening of 
the NZ dollar (2023: $2,780,000 higher), and $2,519,000 lower on a 5% strengthening of the NZ dollar as at 
31 March 2024 (2023: $2,515,000 lower).
Credit risk
Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails 
to meet its contractual obligations. Credit risk arises from cash and cash equivalents and deposits with banks 
and financial institutions, as well as from the Group’s receivables due from customers. Only major banks are 
accepted for cash and deposit balances.
Payment and delivery terms are agreed to within each of the respective customers agreements. Aging of 
payments due from customers are monitored on a regular basis.
Liquidity risk
Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. 
The Group’s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient 
liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring 
unacceptable losses or risking damage to the Group’s reputation.
The following significant exchange rates applied during the year:
Average rate
2024
Average rate
2023
Closing rate
2024
Closing rate
2023
NZD/USD
0.6101
0.6246
0.5991
0.6275

77
The Group manages liquidity risk by continuously monitoring forecast and actual cash flows and matching 
the maturity profiles of financial assets and liabilities.
The tables below analyse the Group’s financial liabilities into relevant maturity groupings based on the 
remaining period at the reporting date to the contractual maturity date. The amounts disclosed in the table 
are the contractual undiscounted cash flows, including interest payments in respect of financial liabilities.
At 31 March 2024
Note
Less than 3 
months
$000
3-12 months
$000
Between 1 
and 2 years
$000
Over 2 
years
$000
Total 
contractual 
cash flows
$000
Total 
carrying 
amounts
$000
Financial liabilities
Trade and other 
payables
13
3,741
-
- 
-
3,741
3,741
Lease liabilities 
16
370
1,113
1,523
6,070
9,076
7,435
Derivative liabilities
507
406
149
-
1,062
1,062
Total
 
4,618
1,519
 1,672
6,070
13,879
12,238
At 31 March 2023
Note
Less than 3 
months
$000
3-12 months
$000
Between 1 
and 2 years
$000
Over 2 
years
$000
Total 
contractual 
cash flows
$000
Total 
carrying 
amounts
$000
Financial liabilities
Trade and other 
payables
13
3,607
-
- 
-
3,607
3,607
Lease liabilities 
16
202
1,024
1,261
6,380
8,867
7,107
Total
 
3,809
1,024
1,261
6,380
12,474
10,714
Capital adequacy
The Board’s aim is to maintain a strong capital base to sustain future development of the business and 
to maintain investor and creditor confidence. The shareholder funds raised to date provide the Group a 
sufficient capital base to continue to grow the business.
22.	 Financial instruments by category 
(i) Non-derivative financial liabilities
The Group recognises all other financial liabilities (including liabilities designated at fair value through 
profit or loss) recognised initially on the trade date, which is the date that the Group become a party to the 
contractual provisions of the instrument.
The Group derecognises a financial liability when its contractual obligations are discharged, cancelled
Wor expire.
The Group classifies non-derivative financial liabilities into the other financial liability category. Such financial 
liabilities are recognised initially at fair value plus any directly attributable transaction costs. Subsequent 
to initial recognition, these financial liabilities are measured at amortised cost using the effective interest 
method.
Other financial liabilities comprise trade and other payables.
(ii) Non-derivative financial assets
The Group initially recognises financial assets at amortised cost on the date that they are originated. 
The Group derecognises a financial asset when the contractual rights to the cash flows from the asset expire, 
or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all the 
risks and rewards of ownership of the financial asset are transferred. Any interest in transferred financial 
assets that is created or retained by the Group is recognised as a separate asset or liability.
Financial assets and liabilities are offset and the net amount presented in the statement of financial position 
when, and only when, the Group has a legal right to offset the amounts and intends either to settle on a net 
basis or to realise the asset and settle the liability simultaneously.
The Group classifies non-derivative financial assets into the following categories: financial assets at fair value 
through other comprehensive income and financial assets at amortised cost. 

Annual Report 2024
(iii) Derivatives
Derivatives are initially recognised at fair value on the date a derivative contract is entered into, and they are 
subsequently remeasured to their fair value. Derivatives are carried in the consolidated statement of financial 
position at fair value with the changes in fair value recognised in the consolidated statement of profit or loss 
in the finance income or expenses. The Group does not apply hedge accounting for derivative contracts.
At 31 March 2024
Note
Assets at 
amortised cost
$000
Assets at 
fair value 
through other 
comprehensive 
income
$000
Total
$000
Assets as per Consolidated Statement
of Financial Position
Cash and cash equivalents
7
11,522
-
11,522
Term deposits
7
18,000
-
18,000
Trade and other receivables
9
13,263
-
13,263
Financial assets at FVTOCI
8
-
703
703
Total financial assets
 
42,785
703 
43,488
At 31 March 2023
Note
Assets at 
amortised 
cost
$000
Assets at 
fair value 
through other 
comprehensive 
income
$000
Assets at fair 
value through 
profit and loss
$000
Total
$000
Assets as per Consolidated Statement
of Financial Position
Cash and cash equivalents
7
9,540
-
-
9,540
Term deposits
7
35,134
-
-
35,134
Trade and other receivables
9
14,092
-
-
14,092
Financial assets at FVTOCI
8
-
1,260
-
1,260
Derivative assets
-
-
192
192
Total financial assets
58,766
1,260 
192
60,218
At 31 March 2024
Note
Liabilities at 
amortised cost
$000
Liabilities at fair 
value through 
profit and loss
$000
Total
$000
Liabilities as per Consolidated Statement 
of Financial Position
Trade and other payables
13
1,709
-
1,709
Lease liabilities 
16
7,435
-
7,435
Derivative liabilities
-
1,061
1,061
Total financial liabilities 
9,144
1,061
10,205
At 31 March 2023
Note
Liabilities at 
amortised cost
$000
Total
$000
Liabilities as per Consolidated Statement 
of Financial Position
Trade and other payables
13
1,909
1,909
Lease liabilities 
16
7,107
7,107
Total financial liabilities 
9,016
9,016

79
(iv) Financial instruments measured at fair value 
The fair value hierarchy of financial instruments measured at fair value is provided below. 
Note
2024
$000
2023
$000
Financial assets
US listed equity securities 
8
703
1,260
Derivative financial (liabilities)/assets
(1,061)
192
The fair value of the listed equity securities is based on published market price (level 1) in the fair value 
hierarchy) and is revalued at reporting date. The fair value of derivative assets is based on level 2 inputs. 
(v) Financial instruments not measured at fair value 
Financial instruments not measured at fair value includes cash and cash equivalents, trade and other 
receivables, trade and other payables. 
Due to their short-term nature, the carrying value of cash and cash equivalents, term deposits, trade and 
other receivables, and trade and other payables approximates their fair value. 
23. Events after the reporting date
There have been no significant events subsequent to reporting date which required disclosure in or adjustment to 
the consolidated financial statements.
24. Other Disclosures 
a. Reconciliation of loss after income tax to cash flow from operating activities
2024
$000
2023
$000
Loss after tax
(10,628)
(396)
Add / (deduct) non-cash items:
Depreciation of property, plant and equipment
1,988
1,798
Depreciation of right of use assets
1,024
807
Gain on disposal of assets 
-
13
Amortisation of intangibles
1,383
1,229
Share based payment expenses 
3,181
2,578
Interest – lease liabilities 
490
378
Unrealised currency losses / (gains) 
1,897
(266)
Movement in working capital:
Movement in provisions
3
6
Movement in tax receivable
(26)
(387)
Movement in trade and other receivables
901
(2,235)
Movement in prepayments and contract assets
(4,424)
(6,393)
Movement in inventories
(3,273)
(2,748)
Movement in trade and other payables
109
1,844
Net cash flows from operating activities
(7,375)
(3,772)

Annual Report 2024
80
b. Reconciliation of changes in liabilities arising from financing activities.
Note
Total lease 
liabilities 2024
$000
Total lease 
liabilities 2023
$000
At 1 April
(7,107)
(5,876)
Cash flow
1,230
1,024
Non-cash flow
Additions during the year
16
(1,068)
(1,877)
Interest accrued during the year
16
(490)
(378)
At 31 March
(7,435)
(7,107)
c. Foreign currency transactions
Foreign currency transactions are translated into the functional currency using the exchange rates prevailing 
at the dates of the transactions.
Foreign exchange gains and losses resulting from the settlement of such transactions and from the 
translation of monetary assets and liabilities denominated in foreign currencies at reporting date exchange 
rates are recognised profit or loss.
Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using 
the exchange rate as at the date of the initial transaction.
Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at 
the date when the fair value was determined and are recognised in Other Comprehensive Income (except on 
impairment in which case foreign currency differences that have been recognised in Other Comprehensive 
Income are reclassified to profit or loss).
d. Goods and services tax (GST)
Revenues and expenses have been recognised in the financial statements exclusive of GST except that 
irrecoverable GST input tax has been recognised in association with the expense to which it relates. All items 
in the Statement of Financial Position are stated exclusive of GST except for receivables and payables which 
are stated inclusive of GST.
e. Capital commitments
As at 31 March 2024, the Group had equipment capital commitments of $867,500 (2023: $3,051,000).
f. Contingent liabilities
As at 31 March 2024, the Group had no significant contingent liabilities (2023: $nil).


Annual Report 2024
ADDITIONAL 
INFORMATION
	
+ Aroa Biosurgery Limited 
Aroa Biosurgery Limited is a New Zealand incorporated company and is 
registered with ASIC as a foreign company. The Company is accordingly 
principally governed by New Zealand law, rather than Australian law. This 
means that the Company’s general corporate activities (apart from any 
offering of securities in Australia and certain reporting and disclosure 
obligations) are not regulated under the Corporations Act by ASIC. They 
are instead regulated in New Zealand by New Zealand law including the 
Companies Act, Financial Markets Conduct Act 2013, Financial Markets 
Conduct Regulations 2014 and by the New Zealand Financial Markets 
Authority and the Registrar of Companies. 
	
+ Stock exchange information and on-market buy-backs
The Company’s shares were officially quoted on the ASX on 24 July 2020 
(ASX Code: ARX). During the year ended 31 March 2024, the Company did 
not seek, or rely upon, any waivers from the ASX Listing Rules. There is no 
current on-market buy-back of the Company’s shares and the Company 
did not undertake an on-market buy-back of its shares during the year 
ended 31 March 2024. 
NZ Company No. 1980577
ARBN 638 867 473

83
	
+ Ordinary shares 
On 31 March 2024 and as at the date of this Annual Report, the Company only has one class of shares on issue, 
being ordinary shares in the Company, each conferring to the registered holder the rights set out in the Company’s 
constitution, including the right to vote on any resolution at a meeting of shareholders. Holders of ordinary shares 
may vote at a meeting, in person or by proxy, representative or attorney. 
The total number of ordinary shares in the Company on issue as at 31 March 2024 was 344,207,834 shares and the 
total number of ordinary shares in the Company on issue as at 31 May 2024 was 344,207,834 shares.
The distribution of shareholdings as at 31 May 2024 is as shown in the table below:
Based on the closing market price of AROA’s ordinary shares on 31 May 2024, the number of shareholdings held 
in less than marketable parcels is 632, representing 322,611 shares. The Company has not carried out any issues of 
securities approved for the purposes of Item 7 of section 611 of the Corporations Act.
	
+ Share options
As at 31 March 2024, there were 28,005,702* share options on issue (representing the same number of unissued 
ordinary shares) held by 95 holders under the NZ Option Plan and US Option Plan. Share options do not carry 
voting rights.    
The distribution of share options as at 31 May 2024 is as shown in the table below:
*excluding the forfeited options at 31 March 2024 for accounting purposes, but not excluded from the options register.
Please refer to the Remuneration Report and note 18 to the consolidated financial statements for further details of 
share options outstanding. 
	
+ Shares issued on exercise of options
The table below outlines ordinary shares issued during FY24 upon exercise of share options granted under the NZ 
Option Plan. No share options issued under the US Option Plan were exercised during the year.  
Under the option plan rules, at the Board’s discretion, options may be exercised by cashless settlement. This 
involves issuing a reduced number of shares to the participant generally equivalent to: (a) an amount equal to 
the difference between the current value of the Company’s shares (being the VWAP for the five trading days 
immediately preceding the option exercise date) and the exercise price of the shares, multiplied by the number 
of options being exercised, and divided by (b) the current value of the Company’s shares.
Size of shareholding
Number of holders
% 
Number of ordinary 
shares
%
1 to 1,000
875
23.62
562,257
0.160
1,001 to 5,000
1,230
33.21
3,422,976
0.990
5,001 to 10,000
587
15.85
4,680,081
1.360
10,001 to 100,000
873
23.57
27,109,322
7.880
100,001 and over
139
3.75
308,433,198
89.610
TOTAL
3,704
100
344,207,834
100.000
Size of holding
Number of holders
%
Number of options
%
1 to 1,000
-
-
-
-
1,001 to 5,000
1
0.42
4,239
0.02
5,001 to 10,000
18
7.63
136,445
0.49
10,001 to 100,000
149
63.14
8,110,924
28.96
100,001 and over
68
28.81
19,754,094
70.54
TOTAL
236
100
28,005,702*
100

Annual Report 2024
	
+ Twenty largest shareholders
The names and holdings of the 20 largest registered shareholders in the Company as at 31 May 2024 
was as follows:
*Share options issued prior to IPO.
Date options exercised
Number of options exercised
Average exercise price 
Number of shares issued
30/08/2023
315,000*
NZ$0.0904
281,934
06/09/2023
50,000
A$0.75
50,000
13/02/2024
157,500*
NZ$0.0979
133,207
27/03/2024
633,225*
NZ$0.10
633,225
Shareholder name
Shareholding
Holding as a % of total ordinary shares on 
issue as at the date above
J P MORGAN NOMINEES AUSTRALIA 
PTY LIMITED
48,251,491
14.01
MR BRIAN WARD & MRS TRACEY 
WARD 
33,125,800
9.62
HSBC CUSTODY NOMINEES 
(AUSTRALIA) LIMITED
32,670,040
9.49
CITICORP NOMINEES PTY LIMITED
32,037,722
9.30
PHIL MCCAW 

19,597,251
5.69
RICHARD ABBOTT 

13,043,020
3.78
BNP PARIBAS NOMS (NZ) LTD
10,520,679
3.05
ASPIRE NZ SEED FUND LTD
10,421,614
3.02
NATIONAL NOMINEES LIMITED
8,010,852
2.32
K ONE W ONE (NO 3) LTD
5,882,550
1.70
CUSTODIAL SERVICES LIMITED 

4,532,679
1.31
SHARON BRYANT 

4,372,267
1.27
HSBC CUSTODY NOMINEES 
(AUSTRALIA) LIMITED - A/C 2
4,138,307
1.20
MR JOHN ANTHONY DELL
3,508,864
1.01
BNP PARIBAS NOMS PTY LTD
3,387,642
0.98
UBS NOMINEES PTY LTD
3,336,270
0.96
BARNABY MAY
3,272,775
0.95
CHRISTOPHER DAVID ASTLEY MILNE 
3,213,022
0.93
K ONE W ONE LTD
3,041,226
0.88
JAMES MCLEAN
2,827,108
0.82
Total Top 20 Holders
249,191,179
72.4
Total Securities
344,207,834

85
	
+ Takeovers and substantial holdings
While the ASX Listing Rules apply to the Company, certain provisions of the Corporations Act do not. The 
Company is not subject to Chapters 6, 6A, 6B and 6C of the Corporations Act dealing with the acquisition of its 
shares (including takeovers and substantial holdings). The New Zealand position under the Takeovers Code (as set 
out in the Takeovers Regulations 2000) and the Financial Markets Conduct Act 2013 is broadly comparable to the 
Australian position in relation to the regulation of takeovers. The New Zealand takeovers regime, not the Australian 
takeovers regime, will apply to the Company as a foreign company. A 20% threshold applies (under which a person 
(together with their associates) is prevented from increasing the percentage of voting rights held or controlled by 
them in excess of that 20% threshold or from increasing an existing holding of more than 20% of the voting rights), 
subject to certain exceptions including, but not limited to, full and partial takeover offers, 5% creep over 12 months 
in the 50% to 90% range, and acquisitions with shareholder approval. Compulsory acquisitions are permitted by 
persons who hold or control 90% or more voting rights in a code company.
Under New Zealand law, there is no requirement for a shareholder of the Company to issue a substantial holding 
notice of holdings above 5%, and because the Company is a New Zealand company the Corporations Act 
provisions regarding substantial shareholder notices do not apply to the Company. However, a shareholder may 
voluntarily disclose such information if it chooses to do so and a number of New Zealand companies listed on 
ASX experience shareholders lodging notices similar to a substantial shareholder notice that is required under the 
Corporations Act notwithstanding there is no requirement to do so. Separately, the Company has undertaken to 
ASX that it will inform the market immediately on becoming aware of a person becoming a Substantial Holder, 
a movement of at least 1% of shares in which the Substantial Holder has a relevant interest and a person ceasing 
to be a Substantial Holder. 
	
+ Limitations on the acquisition of AROA shares
In general, under applicable law securities in the Company are freely transferrable and the only significant 
restrictions or limitations in relation to the acquisition of AROA shares are those imposed by the New Zealand 
takeovers regime (discussed above) and if applicable, the Overseas Investment Act 2005 (NZ) and the Commerce 
Act 1986 (NZ).
AROA’s constitution also permits the directors to (in their absolute discretion) refuse or delay the registration of 
any transfer of AROA shares if permitted to do so by the Companies Act or the ASX Listing Rules. This includes 
(without limitation) if the relevant shares are subject to a holding lock pursuant to the ASX Settlement Operating 
Rules or escrow.
	
+ Substantial shareholders
Set out below is, to the best of the Company’s knowledge, details relating to all Substantial Holders in the 
Company as at 31 May 2024.
*of the Substantial Holder and their “associates” (within the meaning given to that term in 
section 12 of the Corporations Act).
**Brian Ward also holds 3,132,525 unlisted options expiring 23 July 2025 at an exercise 
price of NZ$0.75 per option; 1,217,610 unlisted options expiring 13 November 2027 at a nil 
exercise price; 649,695 unlisted options expiring 13 November 2027 at an exercise price of 
AU$1.165; 453,206 unlisted options expiring 29 February 2028 at a nil exercise price; and 
254,972 unlisted options expiring 29 February 2028 at an exercise price of AU$1.165.
*** The shareholding referenced above reflects holdings by the McSyth Capital Investment 
Trust as well as the McSyth Charitable Foundation Trust, the latter being a registered 
charity of which Phil is one of 2 trustees. He also holds 172,620 unlisted options expiring 
29 February 2028 at an exercise price of AU$1.083 and has an interest in 81,925 unlisted 
options (held by the McSyth Capital Investment Trust) expiring 23 July 2025 at an exercise 
price of AU$0.75 per option.
Shareholder name
Shareholding* 
Holding as a % of total 
ordinary shares on issue
as at 31 May 2024
J P MORGAN NOMINEES AUSTRALIA PTY LIMITED
48,251,491
14.01
MR BRIAN WARD** & MRS TRACEY WARD 
33,125,800
9.62
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED
32,670,040
9.49
CITICORP NOMINEES PTY LIMITED
32,037,722
9.30
PHIL MCCAW  & 
***
19,597,251
5.69

Annual Report 2024
Name
Interest
James McLean
Director, Mesynthes Nominees Limited
Chairman, Prevar Limited
Chairman, R J Hill Laboratories Limited
Brian Ward
Director, Green Edge Limited
Steven Engle
Non-Executive Chairman, Prescient Therapeutics Limited (ASX: PTX)
Director, Author-IT Labs Limited, Author-IT Holdings Limited, Author IT Software 
Corporation Limited and Author-IT Software Corporation
Sole Proprietor, Averigon
CEO & Director, Gradalis Inc
Philip McCaw
Director, Mesynthes Nominee Limited
Director, Author-IT Limited and Author IT Software Corporation Limited
Director, Kaynemaile Ltd
Director, Shift72 Limited
Director, Movac Limited
Director, Movac Fund 4 Custodial Limited
Director, Movac Fund 5 Custodial Limited
Director, Movac Fund 5 General Partner Limited
Director, Movac Fund 4 General Partner Limited
Director, CAVOM Nominee No 1 Limited
Director, Calcium Investments Limited
Director, Calcium Investment Trustee Limited
Director, PJM Management Limited
John Pinion
Advisory Board Member, Celestial Therapeutics, Inc
John Diddams
Non-Executive Chairman, xReality Group Limited (ASX: XRG)
Director, Surf Lakes Holdings Limited
Director, DIT AgTechnologies Limited
	
+ Securities subject to voluntary escrow as at 31 May 2024
As at 31 May 2024, there were no AROA securities subject to voluntary escrow. 
	
+ General disclosure of interests by Directors
AROA maintains an interests register in accordance with the Companies Act. The following are general 
disclosures of interests (pursuant to section 140(2) of the Companies Act) noted in the Company’s interests 
register as at 1 April 2023 which remained current as at 31 March 2024.

87
Company
Directors
Aroa Biosurgery Incorporated (Delaware File number 6560549)
Brian Ward, John Pinion
Mesynthes Nominee Limited (NZBN 9429 041 350 003)
Jim McLean, Phil McCaw
Name
Interest
Nature of update to the Company’s interests register
Philip McCaw
Chief Executive Officer & Board Chair, 
Author-it
Added
Chair, Startup Advisors’ Council 
– New Zealand Government
Removed, the Council was appointed 
for a 12-month term which has expired
Darla Hutton
N/A
Director added to the register, 
but no interest to declare
The following updates to the general disclosures of interests were made during the financial year ended 
31 March 2024:
Details of share dealings by the directors during the 12-month period ended 31 March 2024 are set out in the 
Remuneration Report.
	
+ Use of company information 
AROA did not receive notice from any director requesting to use company information received in his capacity as 
a director of any Group company, which would not otherwise have been available to him.
	
+ Donations
Donations made during the year ended 31 March 2024 totalled NZ$10,000.
	
+ Subsidiary company information
All subsidiary companies in the Group are wholly owned by AROA.
The persons listed below held office as a director of the Company’s subsidiaries during the year ended, and as at, 
31 March 2024. They do not receive any remuneration or other benefits for their role as a director of a Company 
subsidiary.
Other than as disclosed in the Company’s interests register, no entries were made in the interests register of any 
Company subsidiary during the year ended 31 March 2024.
Dr. Catherine Mohr
Director, Carta Healthcare 
Director, Avisi Therapeutics 
Director, FINCA International 
Director, Spark Acquisition 

Annual Report 2024
GLOSSARY 
AND OTHER 
INFORMATION
Term
Description
AROA or the Company
Aroa Biosurgery Limited NZCN 1980577, ARBN 638 867 473
ASIC
Australian Securities and Investments Commission
ASX
Australian Securities Exchange
CC or Constant Currency
Constant currency removes the impact of exchange rate movements. This approach 
is used to assess the AROA group’s underlying comparative financial performance 
without any distortion from changes in foreign exchange rates, specifically the USD. 
The exchange rate of US$0.62/NZ$1.00 has been used in the constant currency 
analysis for FY22/FY23. Unless otherwise specified, all references in this Annual 
Report to ‘constant currency’ or ‘CC’ are as set out here.
CEO
Chief Executive Officer
Companies Act
Companies Act 1993 (NZ)
Corporations Act
Corporations Act 2001 (Cth, Australia) 
ECM
Extracellular matrix
EBIT
Earnings before interest and tax
EBITDA
Earnings before interest, tax, depreciation and amortisation
FDA
The Food and Drug Administration of the US
FY
Financial Year
GPO
Group purchasing organisation
Group
The group of companies comprising AROA, Aroa Biosurgery Incorporated (Delaware 
File number 6560549) and Mesynthes Nominee Limited (NZBN 9429 041 350 003)
IPO
The Company’s initial public offering in July 2020 of 60,000,000 shares in the 
Company at a price of A$0.75 per share
LTI or Long-Term Incentive
A discretionary long-term incentive variable remuneration in the form 
of share options.
NZD
New Zealand Dollar
	
+ Glossary

89
	
+ IP notice
AROA, Aroa Biosurgery, AROA ECM, Endoform, Myriad, Myriad Matrix, Morcells, Myriad Morcells, Myriad Morcells 
Fine, Symphony and Enivo are trademarks of Aroa Biosurgery Limited. All other trademarks are properties of their 
respective owners. ©2024 Aroa Biosurgery Limited.
	
+ References 
1 Guidance assumes an average NZ$/US$ exchange rate of 0.64, compared to the average rate of 0.61 in FY24,
and is subject to TELA Bio delivering on its CY24 revenue guidance of US$74.5-76.5 million.
2 The FY23 figure excludes a ‘one-off’ royalty payment of NZ$1.8 million received from TELA Bio. 
3 Capitalisation in line with the NZ Equivalent to International Accounting Standard 38 (NZ IAS 38).
4 The Board reserves the right to adjust these performance conditions or vesting outcomes to ensure that the 
equity award recipient is neither penalised nor provided with a windfall benefit arising from matters outside their 
control.
5 As a director of Mesynthes Nominee Limited, as at 31 March 2024 Jim McLean also had an interest in 1,514,775 
shares held by Mesynthes Nominee Limited on bare trust for certain AROA employees until payment is received for 
such shares. 
6 Phil McCaw holds his interest through McSyth Capital Investment Trust, of which he is one of 3 trustees and a 
beneficiary. Mr McCaw also has an interest in shares held by the McSyth Charitable Foundation Trust, a registered 
charity of which he is one of 2 trustees. As a director of Mesynthes Nominee Limited, as at 31 March 2024 
Mr. McCaw also had an interest in 1,514,775 shares held by Mesynthes Nominee Limited on bare trust for certain 
AROA employees until payment is received for such shares. 
7 This includes interests in shares held by John Diddams’ related parties; Whitfield Investments Pty Ltd and Galdarn 
Pty Ltd.
8 Brian Ward holds his interest through Arawai No. 2 Trust, of which he is one of 3 trustees and a beneficiary.
NZ GAAP
New Zealand Generally Accepted Accounting Practice
NZ IFRS
New Zealand Equivalents to International Financial Reporting Standards
NZ Option Plan
The Aroa Biosurgery Share Option Plan (NZ)
Shares
Ordinary shares in the Company
Share Plan
The Aroa Employee Incentive Share Plan 2014, which was wound up in 2020
STI or Short-term Incentive
Discretionary short-term bonus providing the potential for an annual cash bonus 
based on pre-determined company and individual performance targets.
Substantial Holder
Has the meaning given to it in the Corporations Act
TAM
Estimated total addressable market
TELA Bio
TELA Bio, Inc. TELA Bio is AROA’s sales and distribution partner licensed for 
abdominal wall reconstruction/hernia and breast reconstruction indications in North 
America and Europe.
US
The United States of America
USD
United States Dollar
US Option Plan
The AROA Biosurgery 2021 US Share Option Plan 
VWAP
The volume weighted average market price for Shares reported on the ASX


91
Directors
Jim McLean, Chair and 
Independent Non-Executive 
Director 
Brian Ward, Founder, 
Chief Executive Officer and 
Managing Director
John Diddams, Independent 
Non-Executive Director
Darla Hutton, Independent 
Non-Executive Director
Philip McCaw, Non-Executive 
Director
Dr. Catherine Mohr, Independent 
Non-Executive Director
John Pinion, Independent 
Non-Executive Director
Joint Company Secretaries
James Agnew, Chief Financial 
Officer and Joint Company 
Secretary
Tracy Weimar, Joint Company 
Secretary
NZ Registered Office
64 Richard Pearse Drive, Mangere, 
Auckland 2022, New Zealand
Telephone: + 64 9 869 3035
Australian Registered Office
Level 1, 357 Military Road,
Mosman NSW 2088
Australia
Telephone: + 61 3 9692 7222
CORPORATE 
DIRECTORY
Auditor
BDO Auckland
Level 4, BDO Centre 
4 Graham Street
Auckland 1010 
New Zealand
New Zealand Legal Adviser
Chapman Tripp
Level 34, PwC Tower
15 Customs Street West
Auckland CBD, Auckland 1140
New Zealand
Australian Legal Adviser
Mills Oakley
Level 7, 151 Clarence Street
Sydney NSW 2000
Australia
Share Registry
Boardroom Pty Limited
Level 8, 210 George Street
Sydney NSW 2000
Contact number if calling from 
inside Australia 1300 737 760
Contact number if calling from 
outside Australia +61 2 9290 9600
Website
www.aroa.com

www.aroa.com
 
©June  2024